

# BMJ Open

## Multicenter open-label randomized controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009956
Article Type:	Protocol
Date Submitted by the Author:	16-Sep-2015
Complete List of Authors:	<p>Dickstein, Yaakov; Rambam Healthcare Campus, Division of Infectious Diseases          Leibovici, Leonard; Rabin Medical Center, Beilinson Hospital, Department of Medicine E          Yahav, Dafna; Rabin Medical Center, Beilinson Hospital, Unit of Infectious Diseases          Eliakim-Raz, Noa; Rabin Medical Center, Beilinson Hospital, Unit of Infectious Diseases          Daikos, George; Laiko General Hospital, First Department of Propaedeutic Medicine          Skiada, Anna; University of Athens, First Department of Medicine          Antoniadou, Anastasia; University of Athens, Fourth Department of Medicine          Carmeli, Yehuda; Tel Aviv Sourasky Medical Centre, Division of Epidemiology and Preventive Medicine          Nutman, Amir; Tel Aviv Sourasky Medical Centre, Division of Epidemiology and Preventive Medicine          Levi, Inbar; Tel Aviv Sourasky Medical Centre, Division of Epidemiology and Preventive Medicine          Adler, Amos; Tel Aviv Sourasky Medical Centre, Microbiology Laboratory          Durante-Mangoni, Emanuele; Second University of Naples, Monaldi Hospital-AORN dei Colli, Internal Medicine          Andini, Roberto; Second University of Naples, Monaldi Hospital-AORN dei Colli, Internal Medicine          Cavezza, Giusi; Second University of Naples, Monaldi Hospital-AORN dei Colli, Internal Medicine          Mouton, Johan; Erasmus MC, Department of Medical Microbiology and Infectious Diseases          Wijma, Rixt; Erasmus MC, Department of Medical Microbiology and Infectious Diseases          Theuretzbacher, Ursula; Center for Anti-Infective Agents,          Friberg, Lena; Uppsala University, Department of Pharmaceutical Biosciences          Kristoffersson, Anders; Uppsala University, Department of Pharmaceutical Biosciences          Dishon, Yael; Rambam Healthcare Campus, Division of Infectious Diseases          Altunin, Sergey; Rambam Healthcare Campus, Division of Infectious Diseases          Paul, Mical; Rambam Healthcare Campus, Division of Infectious Diseases</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Primary Subject Heading:</b>	Infectious diseases
<b>Secondary Subject Heading:</b>	Pharmacology and therapeutics
<b>Keywords:</b>	colistin, combination therapy, meropenem, multidrug resistant Gram-negative bacteria

SCHOLARONE™  
Manuscripts

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2015-009956 on 20 April 2016. Downloaded from <http://bmjopen.bmj.com/> on November 20, 2019 by guest. Protected by copyright.

1  
2  
3 **Multicenter open-label randomized controlled trial to compare**  
4 **colistin alone with colistin plus meropenem for the treatment of**  
5 **severe infections caused by carbapenem-resistant Gram-negative**  
6 **infections (AIDA): study protocol**  
7  
8  
9  
10  
11  
12  
13  
14

15 **Author information:**

16 Yaakov Dickstein<sup>a</sup>, Leonard Leibovici<sup>b,c</sup>, Dafna Yahav<sup>c,d</sup>, Noa Elyakim-Raz<sup>c,d</sup>,  
17 George L. Daikos<sup>e</sup>, Anna Skiada<sup>e</sup>, Anastasia Antoniadou<sup>f</sup>, Yehuda Carmeli<sup>g</sup>, Amir  
18 Nutman<sup>g</sup>, Inbar Levi<sup>g</sup>, Amos Adler<sup>h</sup>, Emanuele Durante-Mangoni<sup>i</sup>, Roberto Andini<sup>i</sup>,  
19 Giusi Cavezza<sup>i</sup>, Johan W. Mouton<sup>j,k</sup>, Rixt A. Wijma<sup>j</sup>, Ursula Theuretzbacher<sup>l</sup>, Lena E.  
20 Friberg<sup>m</sup>, Anders N. Kristoffersson<sup>m</sup>, Yael Dishon<sup>a</sup>, Sergey Altunin<sup>n</sup>, Mical Paul<sup>a,n</sup> and  
21 the AIDA consortium  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Corresponding author: Prof. Mical Paul, Division of Infectious Diseases, Rambam  
34 Healthcare Campus, Haaliya Hashniya 8, Haifa, Israel, email [paulm@post.tau.ac.il](mailto:paulm@post.tau.ac.il),  
35 Tel: 04-7773376.  
36  
37  
38  
39  
40  
41

42 <sup>a</sup> Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel

43 <sup>b</sup> Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva,  
44 Israel  
45  
46  
47

48 <sup>c</sup> Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel

49 <sup>d</sup> Unit of Infectious Diseases, Rabin Medical Center, Beilinson Hospital, Petah Tikva,  
50 Israel  
51  
52  
53  
54

55 <sup>e</sup> First Department of Medicine, University of Athens, Athens, Greece

56 <sup>f</sup> Fourth Department of Medicine, University of Athens, Athens, Greece  
57  
58  
59  
60

<sup>g</sup> Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

<sup>h</sup> Microbiology Laboratory, Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel

<sup>i</sup> Internal Medicine, Second University of Naples, Monaldi Hospital-AORN dei Colli, Napoli, Italy

<sup>j</sup> Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands

<sup>k</sup> Department of Medical Microbiology, Radboudumc, Nijmegen, The Netherlands

<sup>l</sup> Center for Anti-Infective Agents, Vienna, Austria

<sup>m</sup> Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

<sup>n</sup> Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel

**Key words:** Colistin, Combination therapy, Meropenem, Multidrug resistant Gram-negative bacteria

**Word count:** 4290

## ABSTRACT

**Introduction:** The emergence of antibiotic-resistant bacteria has driven renewed interest in older antibacterials, including colistin. Previous studies have shown that colistin is less effective than modern antibiotics and toxic. In-vitro synergy studies and clinical observational studies suggest a benefit of combining colistin with a carbapenem. A randomized controlled study is necessary for clarification, as combination therapy might increase side-effects and further drive carbapenem-resistance in hospitals.

**Methods and analysis:** This is a multicenter, investigator-sponsored, open-label, randomized, controlled 1:1 study comparing colistin monotherapy with colistin-meropenem combination therapy in infections caused by carbapenem-resistant Gram-negative bacteria. The study is being conducted at six centers in three countries (Italy, Greece and Israel). We include patients with hospital- and ventilator-associated pneumonia, blood-stream infections and complicated urinary tract infections. Our primary outcome is clinical success, composed of 14-day survival, hemodynamic stability and clinical stability or improvement. Secondary outcomes include 14- and 28-day mortality as well as other clinical endpoints; safety outcomes will be assessed. A sample size of 360 patients was calculated based on an absolute improvement of 15% in clinical success with combination therapy. Outcomes will be primarily assessed by intention-to-treat. Serum colistin samples are obtained from patients at start of treatment to obtain population pharmacokinetic models. Microbiological sampling includes weekly surveillance samples with analysis of resistance mechanisms and synergy. A concomitant observational trial is evaluating patients who met eligibility requirements but were not randomized in order to assess generalizability of findings.

1  
2  
3 **Ethics and dissemination:** The study was approved by ethics committees at each  
4 participating center and informed consent will be obtained for all patients. The trial is  
5 being performed under the auspices of an independent data and safety monitoring  
6 committee and is included in a broad dissemination strategy regarding revival of old  
7 antibiotics.  
8  
9

10  
11  
12  
13  
14 **Trial registration:** This trial is registered with ClinicalTrials.gov (NCT01732250)  
15 and EudraCT (2012-004819-31).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

### Background and rationale

Colistin, discovered in 1947, has resurged in the last decade for the treatment of multidrug-resistant Gram-negative bacteria (MDR GNB). As a polymyxin, it acts both by disrupting the cell membrane and by binding lipid polysaccharide and blocking the effects of endotoxin [1-2]. Polymyxins are bactericidal by inducing rapid cell death mediated through hydroxyl radical production [3]. Observational studies suggested a higher mortality among patients treated with colistin or polymyxin B compared to patients given other antibiotics, mostly beta-lactams [4-5]. Despite the fact that most of these studies were limited by the probable underdosing of colistin, the pooled rates of nephrotoxicity were higher with colistin compared to other antibiotics [4]. Rates of nephrotoxicity in recent studies designed to assess this outcome have ranged from 6-14% to 32-55%, with much of the difference due to different definitions of renal failure [6-15]. Both the daily dose [12,15] and the total cumulative dose [10-1,16] have been associated with increased risk of nephrotoxicity. Additionally, colistin is associated with neurological toxicity, with more common manifestations including dizziness, muscle weakness, paresthesias, hearing loss, visual disturbances and vertigo [17].

Studies currently focus on improving the efficacy and safety profile of colistin, combination therapy being one commonly adopted strategy. Ideally, a combination regimen should improve clinical success via improved reduction of the bacterial load, more rapid killing, killing or inhibition at lower drug concentrations thus avoiding toxicity and minimizing the risk of resistance selection. Carbapenems are commonly added to colistin in clinical practice for the treatment of infections due to carbapenem-

1  
2  
3 resistant Gram-negative bacteria (CR GNB). Several recent observational studies  
4  
5 concluded that combination therapies including a carbapenem have a significant and  
6  
7 important advantage over colistin monotherapy [18-23]. These studies have been  
8  
9 highly influential on clinical practice worldwide, leading to the view that colistin  
10  
11 should not be used as monotherapy. The limitations of these studies include indication  
12  
13 bias inherent to observational studies comparing treatment regimens, moderate to very  
14  
15 small sample sizes, inclusion of multiple different regimens in the combination arm  
16  
17 and inclusion of carbapenemase-producing carbapenem-susceptible bacteria together  
18  
19 with carbapenem-resistant bacteria [24].  
20  
21  
22  
23  
24

25 To formally appraise the potential benefit of polymyxin-carbapenem combination  
26  
27 therapy, we conducted a systematic review and meta-analysis of their in-vitro  
28  
29 interactions [25]. We found that in time-kill studies, carbapenem-polymyxin  
30  
31 combination therapy showed synergy rates of 77% (95% CI 64-87) for *A. baumannii*,  
32  
33 44% (95% CI 23-51%) for *Klebsiella pneumoniae* and 50% (95% CI 30-69%) for  
34  
35 *Pseudomonas aeruginosa* with low antagonism rates for all. For *A. baumannii*,  
36  
37 meropenem was more synergistic than imipenem, whereas for *P. aeruginosa* the  
38  
39 opposite was true. In studies on single isolates, the use of combination therapy led to  
40  
41 less resistance development in-vitro. Higher synergy rates, observed more frequently  
42  
43 with *A. baumannii* than with *K. pneumoniae* or *P. aeruginosa* strains, could have been  
44  
45 related to lower MICs of *A. baumannii* to carbapenems in general. Differences  
46  
47 between carbapenems were less clear and depended on bacteria type. The systematic  
48  
49 review supported a biological rationale for a clinical trial, along with the selection of  
50  
51 meropenem as the carbapenem of choice in order to maximize the advantage to  
52  
53 combination therapy as *A. baumannii* is the dominant bacterium at the trial sites.  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5 Learning from in-vitro studies on clinical effects is difficult because the bacterial  
6  
7 inocula differ, drug levels may be affected by practical constraints of antibiotic  
8  
9 administration and clinical effects are confounded by underlying conditions and  
10  
11 adverse effects. Previous analyses have shown that despite strong in-vitro proof of  
12  
13 synergy and prevention of resistance selection for beta-lactams and aminoglycosides,  
14  
15 randomized controlled trials did not show a clinical benefit for the same combinations  
16  
17 compared with beta-lactams alone in the treatment of sepsis [26-8]. Furthermore, the  
18  
19 possibility of further resistance selection due to widespread carbapenem usage  
20  
21 following adoption of combination therapy as a policy, increased toxicity and  
22  
23 antagonistic interactions between antibiotics may render combination therapy worse  
24  
25 than monotherapy and not merely non-inferior. Thus, despite in-vitro data supporting  
26  
27 synergy between carbapenems and colistin, proof of improved clinical outcome is  
28  
29 essential.  
30  
31  
32  
33  
34  
35

### 36 **Objectives and Trial Design**

37  
38 Our study was born from the need to examine in an unbiased way whether  
39  
40 combination therapy offers an advantage. To this end, a prospectively designed  
41  
42 randomized controlled trial (RCT) methodology was chosen to enable strict  
43  
44 definitions of the treatment regimens, optimal antibiotic dosing and schedule  
45  
46 definitions and treatment assignment unrelated to infection or patient characteristics.  
47  
48  
49 The primary objective of the trial is to show superiority of colistin-meropenem  
50  
51 combination therapy to colistin monotherapy in the treatment of patients infected with  
52  
53 MDR GNB utilizing an optimal trial design. A secondary objective is to obtain  
54  
55 improved population pharmacokinetic models (PPM) for colistin.  
56  
57  
58  
59  
60

## METHODS AND ANALYSIS

### Setting

We are conducting a multicenter, international study at Laikon and Attikon Hospitals in Athens, Greece; Tel Aviv Medical Center (Tel Aviv), Rabin Medical Center, Beilinson Hospital (Petah-Tikva) and Rambam Health Care Center (Haifa), Israel; and Monaldi Hospital, Naples, Italy. A seventh site at Clinical Center of Serbia, Belgrade, Serbia, is planned for inclusion. Recruitment began in October 2013 and is planned to continue until November 2016.

### Eligibility criteria

#### Inclusion criteria

We include adult inpatients  $\geq 18$  years with ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), complicated urinary tract infections (UTI) or bloodstream infections (BSI) of any source, as defined in Table 1, caused by carbapenem-resistant and colistin-susceptible Gram-negative bacteria, including *Acinetobacter* spp., *P. aeruginosa* or any Enterobacteriaceae (including but not limited to *K. pneumoniae*, *E. coli* and *Enterobacter* spp.). Patient recruitment occurs only after microbiological documentation and susceptibility testing. We include patients with infections caused by carbapenem non-susceptible bacteria (using the EUCAST breakpoint of MIC  $> 2$  mg/L) that are sensitive to colistin (MIC  $\leq 2$  mg/L for *Acinetobacter* spp. and Enterobacteriaceae and  $\leq 4$  mg/L for *Pseudomonas* spp.). We exclude infections when the CR isolate is sensitive to quinolones or any beta-lactam, but include those sensitive to sulbactam, tetracyclines, tigecycline, cotrimoxazole or aminoglycosides as we consider that the latter are not established treatments for severe Gram-negative infections nor has their superiority to colistin been established.

We exclude patients with polymicrobial infections where one or more of the clinically-significant Gram-negative bacteria are susceptible to any beta-lactam as we do not consider it appropriate to treat a beta-lactam-susceptible Gram-negative bacterium with colistin monotherapy given the data available from observational studies on colistin's inferiority to beta-lactams. We permit the inclusion of patients with polymicrobial infections where the non-trial isolate/s are carbapenem-resistant Gram-negative bacteria, Gram-positive bacteria or anaerobes (see permitted additional antibiotics below). Inclusion is based on the testing performed in individual study hospitals after mapping the acceptability of the methods used in participating hospitals. Isolate identification and carbapenem MICs are confirmed in a central laboratory.

**Table 1: Inclusion Criteria for Infections**

Type of infection	Definition
Bloodstream infection (BSI)	Growth of the relevant bacteria in one or more blood culture bottles accompanied by the systemic inflammatory response syndrome (SIRS) within 48h of blood culture taken time. BSIs can be either primary or secondary to any other source of infection.
Ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HAP)	Pneumonia fulfilling CDC/NHSN surveillance definition of health care-associated infection for pneumonia with specific laboratory findings (PNU2) with modifications to the laboratory criteria [29]. Ventilator-associated pneumonia will be defined in persons who had a device to assist or control respiration continuously through a tracheostomy or by endotracheal intubation within the 48-hour period before the onset of infection. BAL will not be performed routinely for the purposes of the trial. The specific criteria required for diagnosis of pneumonia will be all of the following: <ol style="list-style-type: none"> <li>1. Chest radiograph with new or progressive and persistent infiltrate, consolidation or cavitation.</li> <li>2. At least 1 of the following signs of sepsis: Fever &gt;38°C with no other recognized cause; Leukopenia &lt;4000 WBC/mm<sup>3</sup> or leukocytosis &gt;12,000 WBC/mm<sup>3</sup>; For adults &gt;70 years old, altered mental status with no other recognized cause</li> <li>3. At least 1 of the following respiratory signs/symptoms: New onset of purulent sputum or change in character of sputum or increased respiratory secretions or increased suctioning requirements; New onset or worsening cough or dyspnea or tachypnea &gt;25 breaths per minute; Rales or bronchial breath sounds; Worsening gas exchange, including</li> </ol>

	<p>O<sub>2</sub> desaturations, PaO<sub>2</sub>/FiO<sub>2</sub> &lt;240, or increased oxygen requirements</p> <p>4. Laboratory criterion: Growth of the relevant bacteria in culture of sputum, tracheal aspirate, bronchoalveolar lavage or protected specimen brushing. For any lower respiratory secretion other than bronchoalveolar lavage (BAL) or protected specimen brush (PSB), the respiratory sample has to contain &gt;25 neutrophils and &lt;10 squamous epithelial cells per low power field, identified by Gram stain</p>
Probable ventilator-associated pneumonia (VAP)	<p>Pneumonia fulfilling CDC/NHSN 2013 revised surveillance definition, omitting the criterion of antimicrobial treatment before randomization and modifying the microbiological criteria[30]:</p> <ol style="list-style-type: none"> <li>1. Mechanical ventilation for ≥3 calendar days</li> <li>2. Worsening oxygenation, following ≥ 2 calendar days of stable or decreasing FiO<sub>2</sub> or PEEP, presenting as: <ul style="list-style-type: none"> <li>○ Minimum daily FiO<sub>2</sub> values increase ≥ 0.20 (20 points) over baseline and remain at or above that increased level for ≥ 2 calendar days OR</li> <li>○ Minimum daily PEEP values increase ≥ 3 cmH<sub>2</sub>O over baseline and remain at or above that increased level for ≥ 2 calendar days.</li> </ul> </li> <li>3. Temperature &gt; 38 °C or &lt; 36°C, OR white blood cell count ≥ 12,000 cells/mm<sup>3</sup> or ≤ 4,000 cells/mm<sup>3</sup></li> <li>4. Purulent respiratory secretions AND positive respiratory culture; OR positive culture of pleural fluid. For any lower respiratory secretion other than bronchoalveolar lavage (BAL) or protected specimen brush (PSB), the respiratory sample has to contain &gt;25 neutrophils and &lt;10 squamous epithelial cells per low power field, identified by Gram stain.</li> </ol>
Urinary tract infection	<p>Positive urine culture with relevant bacteria ≥10<sup>5</sup> CFU/ml with pyuria, accompanied by the systemic inflammatory response syndrome (SIRS) with 48h of taken time and no other explanation for SIRS</p>

#### Exclusion criteria

We exclude patients treated with colistin for more than 96 hours prior to randomization, but encourage all efforts to recruit patients as soon as possible after identification. The relatively long time period permitted for effective treatment prior to study enrollment was defined to allow maximal patient inclusion in hospitals using colistin empirically and for patients identified during weekends and holidays. In addition, we exclude patients who were previously enrolled in the trial, pregnant women and those with a known allergy to colistin or carbapenems. Originally, we excluded all patients with seizures because of the fear of inducing seizures with high-

1  
2  
3 dose meropenem. Subsequently, we introduced an amendment to exclude only those  
4  
5 who have a history of prior carbapenem-induced seizures and epileptic patients  
6  
7 requiring chronic antiepileptic treatment unless treated previously with a carbapenem  
8  
9 for more than 48 hours without experiencing a seizure. The amendment was  
10  
11 supported by clinical practice in the study centers when treating other patients at risk  
12  
13 for carbapenem-induced seizures.  
14  
15

### 16 17 18 **Interventions** 19

20  
21 At the time of the protocol design, pharmacokinetic (PK) studies demonstrated that it  
22  
23 takes about 36-48 hours for colistin to reach therapeutic concentrations in plasma ( $\geq 2$   
24  
25 mg/L) using classical dosing in patients with normal renal function [31-2]. Thus, a  
26  
27 loading dose equal to the approximate total daily dose was suggested [33].  
28

29  
30 Furthermore, these studies demonstrated that once or twice daily dosing is probably  
31  
32 sufficient. We tailored the colistin administration regimen in the trial according to  
33  
34 these data [34].  
35  
36

### 37 38 **Colistin arm** 39

40  
41 Patients receive a loading dose of 9 MIU, regardless of renal function. For patients  
42  
43 with normal renal function ( $\text{CrCl} \geq 50$  ml/min), the loading dose is followed by 4.5  
44  
45 MIU q12hr [32, 35] beginning 12 hrs. after the loading dose. Colistin is administered  
46  
47 as a 30 minute intravenous infusion. Patients treated with colistin before  
48  
49 randomization are given a loading dose if treated for <48 hours and not given a  
50  
51 loading dose at the start of treatment. Patients who previously received a loading dose  
52  
53 or who have been treated for 48 hours or more continue colistin without a loading  
54  
55 dose, using the trial schedule. Maintenance dose adjustment for patients with renal  
56  
57  
58  
59  
60

failure is based on the study by Garoznik et al.[31] aiming to achieve a colistin steady state average level of 2-2.5 mg/L (Table 2).

**Table 2: Drug dosing schedule**

Renal function	Colistin maintenance dose <sup>1</sup>	Meropenem dosing
CrCl $\geq$ 50 ml/min <sup>2</sup>	4.5 MIU q12h	2 gr q8hr
CrCl <50 ml/min, without renal replacement therapy	Total daily dose in MIU = $[2*(1.5*CrCl + 30)]/30$	CrCl 26-50 ml-min: 2 gr q12hr CrCl 10-25 ml/min: 1 gr q12hr
Continuous renal replacement therapy	Fixed dose of 6 MIU q12h	1 gr q12hr
Intermittent hemodialysis	1 MIU q12h, with a 1 MIU supplemental dose after dialysis	1 gr q24hr with a supplemental dose given after dialysis

<sup>1</sup> All patients receive a loading dose of 9MIU regardless of renal function. Adjustment refers only to the maintenance dose started 12 hrs. after the loading dose

<sup>2</sup> CrCl should be expressed in ml/min/1.73 m<sup>2</sup>, using the MDRD formula, Cockcroft and Gault equation or other means.

#### Combination arm

Colistin is administered as above and combined with IV meropenem 2gr q8hr for patients with normal renal function (CrCl>50 ml/min). Meropenem is administered as a prolonged infusion over 3 hr. For patients with impaired renal function, dosing is adjusted (Table 2) [36]. No dosage adjustments are performed for hepatic insufficiency for either antibiotic. Duration of antibiotic treatment is 10 days for all listed indications. If infectious complications mandate longer treatment, duration is prolonged as appropriate. We permit the concomitant administration of the following antibiotics for polymicrobial infections in both study arms: vancomycin, oxacillin

derivatives, cefazolin, ampicillin, penicillin or metronidazole. We do not permit the routine addition of rifampin, tigecycline, minocycline, aminoglycosides or colistin inhalations.

## Outcomes

The primary outcome is clinical success measured at 14 days from randomization.

The outcome is a composite of survival, hemodynamic stability, respiratory status for patients with pneumonia and microbiological cure for patients with bacteremia and improvement of the Sequential Organ Failure Assessment (SOFA) score (Table 3).

The outcome was defined by consensus of the trial researchers after reviewing published outcome definitions for HAP/VAP [37] and FDA and EMA guidance on the design of clinical trials of antibacterials [38]. Secondary outcomes include 14 and 28-day all-cause mortality; clinical success without modification of the assigned antibiotic regimen; and other outcomes as defined in Table 3, addressing other clinical and microbiological outcomes, resistance development through colonization surveillance, superinfections and adverse events.

**Table 3: Definition of Terms in Outcome**

Term	Definition
Clinical success	Composite of: <ul style="list-style-type: none"> <li>• Patient alive</li> <li>• Systolic blood pressure &gt;90 mmHg without need for vasopressor support</li> <li>• Stable or improved SOFA score, define as:               <ul style="list-style-type: none"> <li>○ for baseline SOFA <math>\geq 3</math>: a decrease of at least 30%;</li> <li>○ for baseline SOFA &lt;3: stable or decreased SOFA score</li> </ul> </li> <li>• For patients with HAP/VAP, PaO<sub>2</sub>/FiO<sub>2</sub> ratio stable or improved</li> <li>• For patients with bacteremia, no growth of the initial isolate in blood cultures taken on day 14 if patient still febrile</li> </ul>
Clinical success without modification	Clinical success, as defined above, but any modification to the antibiotic treatment not permitted by protocol will also be considered as failure. This will include any change or addition of antibiotics not permitted by study protocol during the first 10 days after randomization. Early discontinuation of antibiotic treatment will not be considered as failure.

Time to defervescence	Time to reach a temperature of <math><38^{\circ}\text{C}</math> with no recurrence for 3 days
Change in functional capacity	Function capacity will be classified into 3 grades: 1. Independent 2. Need for assistance for activities of daily living 3. Bedridden
Microbiological failure	Isolation of the initial isolate (phenotypically identical) in a clinical sample (blood or other) 7 days or more after start of treatment or its identification in respiratory samples. For all patients with VAP/HAP sputum or tracheal aspirates will be obtained on day 7, regardless of clinical response. For all patients with UTI, a repeat urine culture will be obtained on day 7, regardless of clinical response. For patients with bacteremia, blood cultures will be repeated on day 7 and 14, only if the patient is febrile at that time.
Superinfection	A new clinically or microbiologically-documented infections by CDC criteria within 28 days
Colonization	Assessed by rectal surveillance (see surveillance protocol under "Microbiological Methods" in the appendices)
CDAD	Diarrhea with a positive <i>C. difficile</i> toxin test
Renal failure	Renal failure using the RIFLE GFR criteria [39] at day 14 and day 28

### PK assessment

Two blood samples for colistin levels are obtained from all patients included in the trial. The 1<sup>st</sup> sample is obtained 15 min. after the end of the loading dose (45 min. from its start). The 2<sup>nd</sup> sample is obtained 2 hrs. before the 3<sup>rd</sup> colistin dose (22 hrs. from the start of the loading dose). For patients treated with colistin before randomization, samples are taken 15 min. following the first post-randomization dose and 2 hrs. prior to the third. This sparse sampling strategy was deemed to provide the most information on individual colistin exposure based on practical constraints, previous modeling of colistin PK [30, 35] and optimal design methodology [40]. Meropenem concentrations are determined in the same samples for those patients who received combination therapy. Plasma samples are frozen immediately at the study centers and sent for analysis of colistin at a central laboratory in Uppsala University,



Sweden and from there to Erasmus MC for assessment of meropenem concentrations where applicable.

## Participant timeline

**Table 4: Participant timeline for RCT**

Day <sup>1</sup>	Enrollment and randomization	Background and clinical information	Colistin levels	Clinical follow-up	Outcome data	Rectal surveillance swabs	Blood cultures if febrile	Other microbiological data sampling <sup>2</sup>
0	X							
1		X	X			X		X
2				X			X	
5				X			X	
7					X	X	X	X
9				X			X	
10				X			X	
14					X	X	X	
21						X		
28					X	X		

<sup>1</sup>Day from randomization; day 1 = 24 hours following randomization

<sup>2</sup>Index culture on day 1; Sputum for HAP/VAP patients and urine for UTI patients on day 7

## Sample size and recruitment

The expected mortality in our trial cohort is approximately 30%, based on previous studies [41-3]. A re-analysis of a cohort study by the researchers indicated a 45% failure rate (no success) for our primary composite outcome [5]. To show an improvement in clinical success (primary outcome) from 55% with colistin alone to 70% with combination therapy with a 1:1 randomization ratio, a sample of 324 patients (162 per group) is needed (uncorrected chi-squared test, alpha=0.05, power=0.8, PS Power and Sample Size Calculations). Assuming a non-evaluability rate of about 10%, we plan to recruit 360 patients.

## Randomization

1  
2  
3 Randomization is performed at the bed-side using a custom-built, dedicated web  
4 application, by using randomized permuted blocks of varying length, stratified by  
5 center. Furthermore, the first block in each strata begins at a random position [44].  
6  
7 Each randomization attempt requires entry of a matching unique ID from the Epi-Info  
8 case report form (CRF; see below, data collection), and each randomization attempt is  
9 logged. No blinding is used after randomization.  
10  
11

### 12 **Data collection and microbiological sampling**

13 We designed a case report form using the Epi-Info free software package  
14 (<http://wwwn.cdc.gov/epiinfo/>). A database is kept at each site, from which  
15 anonymized data are exported periodically and sent to the study primary investigator.  
16  
17 See Table 5 for a list of the data to be collected and participant timeline above. For  
18 assessment of microbiological response, synergy and resistance development we  
19 obtain (in addition to the index culture defined for trial inclusion) a sample from the  
20 primary source of isolation of the CRGNB on day 7 and rectal swabs for CRGNBs  
21 isolation on days 1,7,14 and 28; samples are collected from all patients. Blood  
22 cultures are repeated every 48 hrs. as long as the patient is febrile. Other samples are  
23 obtained as clinically indicated. The index isolate as well as all phenotypically-  
24 identical repeat isolates are kept for further analyses. Samples are frozen and analyzed  
25 centrally at Tel-Aviv Medical Center in Israel.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 **Table 5: Data Collected for RCT Patients**

- |  |
|--|
| <ul style="list-style-type: none"><li>51 • Patient demographics</li><li>52 • Background conditions, including the revised Charlson comorbidity index [45] and McCabe score</li><li>53 • Source of infection and diagnostic criteria for VAP and HAP including type of respiratory<br/>54 specimen used for patient classification</li><li>55 • Devices present at infection onset and risk factors for MDR colonization and infection</li><li>56 • Antibiotic treatment prior to onset of the infectious episode, empirical antibiotic treatment and all</li></ul> |
|--|
- 57  
58  
59  
60

antibiotics used from randomization until day 28. We will document colistin administration times.

- Concomitant nephrotoxic agents: aminoglycosides, IV contrast material, cyclosporine
- Therapeutic procedures throughout the infectious episode (surgery, catheter extraction, etc.)
- Use of colistin inhalation therapy
- SOFA score
- All outcomes as defined

### Statistical analysis

The primary analysis will be by intention-to-treat for all randomized patients by their treatment assignment. A secondary analysis, per protocol, will be defined for patients surviving at least 48 hrs. and receiving at least 5 days of the assigned antibiotic regimen (type and dose) or until death if death occurs between days 3-5, without concomitant antibiotics active against the CR-GNB. Predefined subgroup analyses for the primary and mortality outcomes include:

- Patients who did not receive covering antibiotic treatment in the first 48 hours after culture taken date (patients receiving inappropriate empirical antibiotic treatment)
- Patients with VAP/HAP or bacteremia (excluding probable VAP and UTI)
- Patients in whom the infecting bacteria has an MIC to meropenem <16 mg/L

Baseline characteristics and outcomes of the study groups will be compared.

Significance will be set at  $p=0.05$  and all tests will be 2-sided. Time-to-event outcomes will be assessed using survival analysis. We will conduct a multivariable analysis of the randomized cohort and the randomized + observational cohorts (see below), to examine the independent effect of the study regimen on 28-day mortality.

A pharmacokinetic/pharmacodynamic (PK/PD) analysis is also planned, using the same outcomes, but PK/PD parameter estimates of individual patients as exploratory variables.

### Concomitant observational study

Previous studies have found that the patients included in randomized controlled trials of antibiotics differ significantly from patients encountered in clinical practice, particularly amongst the critically ill [46-7]. This difference threatens the external validity and therefore the generalizability of the findings in these trials. In order to examine the external validity of the present trial and to provide an observational comparison between the trial treatment regimens in the overall cohort, we are collecting all clinical data and treatment regimens from patients not included in the RCT for the reasons detailed in Table 6 but otherwise fulfilling clinical and microbiological inclusion criteria. Treatment in this arm is based on attending physicians' decisions. Clinical and microbiological samples for these patients are collected only for routine purposes and are neither kept nor analyzed as for the main trial. Data are kept anonymously. Informed consent for data collection are not required, as no intervention is planned.

**Table 6: Eligibility Criteria for Observational Trial**

- Unable to provide informed consent or otherwise no informed consent
  - Identified later than 96h after start of treatment
  - Second and subsequent episodes of infection for patients included in the RCT.
- A separate episode of infection will be defined as an infection occurring at least 28 days after the index episode of infection and separated by at least 7 days of antibiotics.

### Data and safety monitoring

The present trial is part of the larger AIDA project which is designed to assess the efficacy and safety of old, revived antibiotics in the treatment of infections with antibiotic-resistant bacteria. As such, the trial is being performed under the auspices of the data and safety monitoring committee (DSMC) of the AIDA project which is independent of the organizers of both the study and the AIDA project. The DSMC has full access to trial data for review. In addition, there will be three yearly evaluations over the course of the trial at which a summary of trial procedures to date will be presented.

No interim analyses are planned. In our trial, the risks that the trial arm (combination therapy) is associated with significantly better or worse outcomes than the control arm (monotherapy) such that an interim analysis would lead to early stopping were assessed as low. The possibility that an interim analysis would indicate that the study is under-powered, thus necessitating an increase in participant numbers, was deemed irrelevant due to logistical considerations.

## ETHICS AND DISSEMINATION

The study was approved by the ethics committees at each participating center and informed consent will be obtained for all patients. Recognizing that many of the patients eligible for the study are not able to provide informed consent at the time antibiotics should be started, we tried to find solutions to avoid excluding this large patient population. In Italy and Greece a relative can provide informed consent for the patient. In Israel, only a legal guardian assigned by a court of law is qualified for informed consent. However, the ethics committees in all study sites in Israel approved the study as “emergency research”. Such an approval is granted for trials in which (1) the patient is in an immediate life-threatening condition, existing treatments are unsatisfactory, it is important to define optimal treatment for the condition and the study could not have been performed had informed consent been required; (2) the patient’s life-threatening condition requires treatment and pre-clinical studies point in favor of the intervention assessed; (3) it is impossible to obtain informed consent from the patient because of the acute condition and treatment has to be provided in a time-window that does not allow assigning a legal guardian. We showed that antibiotic treatment for severe infections such as bacteremia and VAP caused by CRGNB fulfill all these criteria. In emergency trials, the investigator has to guarantee that all efforts be made to obtain informed consent from the patient or a legal guardian in the appropriate time-window and if impossible the investigator and an “independent” physician (providing direct patient care but not participating in the study) sign informed consent for the patient. The researcher is obliged to request informed consent from the patient once the acute condition is reversed. It is mandated that an independent data monitoring and safety committee and the ethics committee follow the trial.

1  
2  
3  
4  
5 The trial was registered with the National Institutes of Health (NIH) trial registry  
6  
7 (NCT01732250; registered on 19 November 2012) and European Union Drug  
8  
9 Regulating Authorities Clinical Trials (EudraCT) registry (2013-005583-25;  
10  
11 registered on 8 July 2013) before the start of the trial.  
12  
13

14  
15  
16 The study investigators pioneered a coordinated initiative to “re-develop” old, now  
17  
18 resurgent antibiotics that have never been analyzed in a structured process for drug  
19  
20 assessment and regulatory approval meeting current scientific standards. They  
21  
22 organised an international conference to raise broad awareness about this issue and  
23  
24 addressed the need for a structured process to fill the knowledge gaps for old revived  
25  
26 antibiotics [48]. A series of publications highlighted a range of topics regarding old  
27  
28 antibiotics [49-54]. Similarly, study investigators actively participated in the 1<sup>st</sup> and  
29  
30 2<sup>nd</sup> international polymyxin conferences, where the study protocol and progress were  
31  
32 discussed [55]. A range of dissemination activities are planned or ongoing, including  
33  
34 educational courses dedicated to advances in optimizing the use of colistin and other  
35  
36 revived antibiotics as well as presentations and educational workshops at international  
37  
38 conferences. Ongoing PK analyses, an integral part of the colistin study, are being  
39  
40 presented at international conferences. We will publish the final report of the study.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

The present trial is part of the larger AIDA project which has been designed to analyze the clinical effectiveness and optimal dosing of older antibiotics, including colistin, fosfomycin, nitrofurantoin, minocyclin and rifampicin (see [www.aida-project.eu](http://www.aida-project.eu)). Within this wider framework two further randomized-controlled trials are underway as well as a series of linked microbiological and PK/PD studies. The linked microbiological study of our trial will examine the effect of treatment regimen on density of resistant strains and the co-carriage of various carbapenem-resistant strains. Co-carried resistant strains belonging to different species and newly-acquired resistant strains will be further studied for mechanisms of resistance. An analysis is planned to examine correlations between carbapenem MICs, colistin MICs, molecular typing, mechanisms of resistance and synergy studies with treatment outcomes including clinical success, microbiological failure, and emergence of resistance. PK studies completed after the launch of our trial challenge the need for a loading dose [56]. We hope that new PK data generated on a large sample of patients during the course of the present trial will help to provide a definitive answer. In the linked PK/PD study we plan to improve population pharmacokinetic models (PPM) for colistin, predict exposures in individual patients using PPM and in the population by Monte Carlo simulations, correlate exposures with outcomes (efficacy and emergence of drug resistance) for colistin monotherapy vs. combination therapy and determine cut-offs of pharmacodynamic indices using Classification and Regression Tree (CART) analysis and logistic regression analysis, determine target exposures for each drug and combinations in preclinical models and suggest clinical breakpoints.



1  
2  
3 A concurrent NIH-funded randomized controlled trial is being conducted in the US,  
4 assessing similar interventions and using comparable microbiological methods  
5 (NCT01597973). An agreement has been reached between the NIH trial and the  
6 present trials' primary investigators to examine possible collaboration. We are trying  
7 to ensure comparability between the current and the NIH trial, in particular with  
8 respect to the outcomes assessed to allow for comparison and compilation of results  
9 after analysis of the current trial. We will pool results using methods of individual  
10 patient level meta-analysis.  
11  
12  
13  
14  
15  
16  
17  
18  
19

20  
21  
22 Antibiotic approval trials are predominantly indication-based, focusing on a single  
23 indication such as VAP, complicated UTI, etc. Our trial is pathogen-based,  
24 comprising a spectrum of infections that are caused by carbapenem-resistant Gram-  
25 negative bacteria and for which colistin is utilized. Though our trial design is focused  
26 on practicability and on mirroring clinical practice, it may offer valuable experience  
27 for future pathogen-directed designs in critically ill patients that need to meet  
28 regulatory requirements based on EMA's 2013 guideline. A problem may arise in  
29 trials focusing on pathogens if treatment effects differ significantly for different sites  
30 of infection. PK models of different infection sites as well as pooling results with the  
31 NIH trial to allow for subgroup analyses by types of infections may support the  
32 validity of the results of a pathogen-focused trial.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49  
50 Until recently FDA and EMA guidelines addressed outcomes by indication only; as  
51 our trial addresses several indications, previously recommended outcome definitions  
52 were inadequate. We sought an outcome that would reflect a clinically-significant  
53 benefit for critically-ill patients, recognizing that survival is a key outcome in this  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 population. The proximity to randomization (14-day outcome as currently  
4  
5 recommended for severe infections) increases the chances that mortality is related to  
6  
7 the infection and its treatment.  
8  
9

10  
11 During the process of obtaining approval for this trial at the participating sites, it  
12  
13 became clear that numerous differences exist between the regulatory requirements of  
14  
15 the countries involved. Amongst these is the approach to informed consent in  
16  
17 incapacitated patients. The Declaration of Helsinki states "For a potential research  
18  
19 subject who is incapable of giving informed consent, the physician must seek  
20  
21 informed consent from the legally authorised representative" [57]. In most countries  
22  
23 involved in the present study a relative is an acceptable surrogate which renders  
24  
25 clinical trials among incompetent patients feasible. At the Israeli sites on the other  
26  
27 hand, the representative must be someone with court-appointed power of attorney  
28  
29 over the patient's person. For patients who cannot provide consent and for whom a  
30  
31 representative is lacking, the Declaration of Helsinki states that "the study may  
32  
33 proceed without informed consent provided that the specific reasons for involving  
34  
35 subjects with a condition that renders them unable to give informed consent have been  
36  
37 stated in the research protocol and the study has been approved by a research ethics  
38  
39 committee". Despite this, none of the European countries participating in the trial has  
40  
41 mechanisms in place to provide for these patients.  
42  
43  
44  
45  
46  
47  
48

49 The implications of the above differences are ethical, methodological and practical.  
50  
51 Certainly it is desirable that the patient's medical surrogate have the patient's best  
52  
53 interests at heart as well as share common values with the patient regarding issues  
54  
55 related to medical decision-making. While the precise genealogical relationship  
56  
57  
58  
59  
60

1  
2  
3 between two individuals is not a guarantor of these ideals, a system needs to be in  
4  
5 place to ensure them. Although the law could automatically label any relative as  
6  
7 having decision-making power, thus giving them the qualification of "legally  
8  
9 authorized representative", such a practice may be ethically questionable. The  
10  
11 provision of a legal framework for recruiting incapacitated patients without decision-  
12  
13 makers is ethically sound since it allows for these patients to potentially benefit from  
14  
15 experimental treatments. Lack of a framework on the other hand effectively excludes  
16  
17 their participation, denying any possible benefits. Methodologically, it biases studies  
18  
19 towards less severely-ill patients, thus denying not only current patients the potential  
20  
21 benefits of new therapies but also leading to uncertainty regarding their costs and  
22  
23 benefits in similar patients in the future. Finally, on a practical level it makes it more  
24  
25 difficult for researchers to conduct studies on the populations most in need of new  
26  
27 therapeutics.  
28  
29  
30  
31  
32

### 33 34 **TRIAL STATUS**

35  
36 To date 240 patients, or 67% of the planned total, have been recruited within 25  
37  
38 months (of a planned 36), including 178 in Israel, 40 in Greece and 22 in Italy. Due to  
39  
40 bureaucratic delays, the center in Italy began participation more than a year after trial  
41  
42 commencement. An additional 204 patients (175 in Israel, 27 in Greece and 2 in Italy)  
43  
44 have been recruited into the observational trial.  
45  
46  
47

### 48 49 **AUTHORS' CONTRIBUTIONS**

50  
51 Study conception and design: all authors. Manuscript draft: Yaakov Dickstein, Mical  
52  
53 Paul. Critical review and revision of the final manuscript: all authors.  
54  
55

### 56 57 **FUNDING**

1  
2  
3 This work was supported by the European Commission FP7 AIDA project  
4  
5 (Preserving old antibiotics for the future, Health-F3-2011-278348).  
6  
7  
8

9  
10 **COMPETING INTERESTS**

11 The authors declare that they have no competing interests.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Zhang L, Dhillon P, Yan H, et al. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2000;44:3317-21.
2. Hughes B, Madan BR, Parratt JR. Polymyxin B sulphate protects cats against the haemodynamic and metabolic effects of *E. coli* endotoxin. *Br J Pharmacol* 1981;74:701-7.
3. Sampson TR, Liu X, Schroeder MR, et al. Rapid killing of *Acinetobacter baumannii* by polymyxins is mediated by a hydroxyl radical death pathway. *Antimicrob Agents Chemother* 2012;56:5642-9.
4. Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic. *Clin Microbiol Infect* 2012;18:18-29.
5. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. *J Antimicrob Chemother* 2010;65:1019-27.
6. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. *BMC Infect Dis* 2005;5:1.
7. Falagas ME, Kasiakou SK, Kofteridis DP, et al. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. *Eur J Clin Microbiol Infect Dis* 2006;25:596-9.
8. Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. *J Infect* 2008;56:185-90.
9. Cheng CY, Sheng WH, Wang JT, et al. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. *Int J Antimicrob Agents* 2010;35:297-300.
10. Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. *Int J Antimicrob Agents* 2005;26:504-7.
11. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. *Clin Infect Disease* 2009;48:1724-8.

12. Deryke CA, Crawford AJ, Uddin N, et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. *Antimicrob Agents Chemother* 2010;54:4503-5.
13. Kim J, Lee KH, Yoo S, et al. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. *Int J Antimicrob Agents* 2009;34:434-8.
14. Ko H, Jeon M, Choo E, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. *Nephron Clin Pract* 2011;117:c284-8.
15. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. *J Infect* 2011;62:187-90.
16. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. *Ann Intern Med* 1970;72:857-68.
17. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. *Crit Care* 2006;10:R27.
18. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing *Klebsiella pneumoniae*: superiority of combination antimicrobial regimens. *Antimicrob Agents Chemother* 2012;56:2108-13.
19. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. *Clin Infect Dis* 2012;55:943-50.
20. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant *Acinetobacter baumannii* bloodstream infections. *Eur J Clin Microbiol Infect Dis* 2014;33:1311-22.
21. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. *Antimicrob Agents Chemother* 2014;58:2322-8.
22. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study. *J Antimicrob Chemother* 2015;70:2133-43.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
23. Rigatto MH, Vieira FJ, Antchevis LC, et al. Polymyxin B in combination with in vitro non-susceptible antimicrobials versus polymyxin B in monotherapy in critically ill patients with *Acinetobacter baumannii* or *Pseudomonas aeruginosa* infections. *Antimicrob Agents Chemother* Published Online First: 10 August 2015. pii:AAC.00494-15.
  24. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. *J Antimicrob Chemother* 2014;69:2305-9.
  25. Zusman A, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. *Antimicrob Agents Chemother* 2013;57:5104-11.
  26. Marcus R, Paul M, Elphick H, et al. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. *Int J Antimicrob Agents* 2011;37:491-503.
  27. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. *BMJ* 2003;326:1111.
  28. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. *BMJ* 2004;328:668.
  29. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control* 2008;36:309-32.
  30. Centers for Disease Control and Prevention (CDC). Improving Surveillance for Ventilator-Associated Events in Adults 2012. [www.cdc.gov/nhsn/PDFs/vae/CDC\\_VAE\\_CommunicationsSummary-for-compliance\\_20120313.pdf](http://www.cdc.gov/nhsn/PDFs/vae/CDC_VAE_CommunicationsSummary-for-compliance_20120313.pdf). Accessed 22 July 2015.
  31. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. *Antimicrob Agents Chemother* 2011;55:3284-94.
  32. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous

- administration in critically ill patients with infections caused by gram-negative bacteria. *Antimicrob Agents Chemother* 2009;53:3430-6.
33. European Medicines Agency completes review of polymyxin-based medicines.  
[http://www.ema.europa.eu/ema/index.jsp?curl=pages/news\\_and\\_events/news/2014/10/news\\_detail\\_002194.jsp&mid=WC0b01ac058004d5c1](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002194.jsp&mid=WC0b01ac058004d5c1). Accessed 25 August 2015.
34. Couet W, Grégoire N, Marchand S, et al. Colistin pharmacokinetics: the fog is lifting. *Clin Microbiol Infect* 2012;18:30-9.
35. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulphonate in critically ill patients: population pharmacokinetics, protein binding and prediction of bacterial kill. *Antimicrob Agents Chemother* 2012;56:4241-9.
36. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. *Clin Infect Dis* 2008;47(Suppl 1):S32-40.
37. Infectious Diseases Society of America (IDSA), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), et al. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. *Clin Infect Dis* 2010;51(Suppl 1):S150-70.
38. Powers JH. Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia. *Clin Infect Dis* 2010;51(Suppl 1):S18-28.
39. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204-12.
40. Kristofferson AN, Friberg LE, Nyberg J. Inter occasion variability (IOV) in individual optimal design (OD). PAGE 22 (2013) Abstr 2689 [www.page-metting.org/?abstract=2689].
41. Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. *Emerg Infect Dis* 2014;20:1170-5.



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
42. Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by *Klebsiella pneumoniae*. *J Hosp Infect* 2013;83:307-13.
  43. Balkan II, Aygün G, Aydın S, et al. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. *Int J Infect Dis* 2014;26:51-6.
  44. Efirid J. Blocked randomization with randomly selected block sizes. *Int J Environ Res Public Health* 2011;8:15-20.
  45. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. *Am J Epidemiol* 2011;173:676-82.
  46. Falagas ME, Pitsouni EI, Bliziotis IA. Trends in the methodological quality of published randomized controlled trials on antibacterial agents. *Br J Clin Pharmacol* 2008;65:942-54.
  47. Zimmermann JB, Horscht JJ, Weigand MA, et al. Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: observational study focus on tigecycline. *Int J Antimicrob Agents* 2013;42:436-42.
  48. Theuretzbacher U, Van Bambeke F, Cantón R, et al. Reviving old antibiotics. *J Antimicrob Chemother* 2015;70:2177-81.
  49. Theuretzbacher U, Paul M. Revival of old antibiotics: structuring the re-development process to optimize usage. *Clin Microbiol Infect* Published Online First: 25 June 2015. doi: 10.1016/j.cmi.2015.06.019.
  50. Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens in special populations. *Clin Microbiol Infect* Published Online First: 14 May 2015. doi: 10.1016/j.cmi.2015.05.002.
  51. Laterre PF, François B. Strengths and limitations of industry vs. academic randomised controlled trials. *Clin Microbiol Infect* Published Online First: 13 July 2015. doi: 10.1016/j.cmi.2015.07.004.
  52. Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin. *Clin Microbiol Infect* Published Online First: 28 May 2015. doi: 10.1016/j.cmi.2015.05.022.

- 1  
2  
3 53. Andersson DI. Improving predictions of the risk of resistance development  
4 against new and old antibiotics. *Clin Microbiol Infect* Published Online First:  
5 21 May 2015. doi: 10.1016/j.cmi.2015.05.012.  
6  
7  
8 54. Muller AE, Theuretzbacher U, Mouton JW. Use of old antibiotics now and in  
9 the future from a pharmacokinetic/pharmacodynamic perspective. *Clin*  
10 *Microbiol Infect* Published Online First: 17 June 2015. doi:  
11 10.1016/j.cmi.2015.06.007.  
12  
13 55. Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use  
14 of colistin and polymyxin B: the Prato polymyxin consensus. *Lancet Infect Dis*  
15 2015;15:225-34.  
16  
17 56. Grégoire N, Mimoz O, Mégarbane B, et al. New colistin population  
18 pharmacokinetic data in critically ill patients suggesting an alternative loading  
19 dose rationale. *Antimicrob Agents Chemother* 2014;58:7324-30.  
20  
21 57. World Medical Association. World Medical Association Declaration of  
22 Helsinki: Ethical Principles for Medical Research Involving Human Subjects.  
23 *JAMA* 2013;310:2191-4.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Multicenter open-label randomized controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009956.R1
Article Type:	Protocol
Date Submitted by the Author:	17-Feb-2016
Complete List of Authors:	<p>Dickstein, Yaakov; Rambam Healthcare Campus, Division of Infectious Diseases          Leibovici, Leonard; Rabin Medical Center, Beilinson Hospital, Department of Medicine E          Yahav, Dafna; Rabin Medical Center, Beilinson Hospital, Unit of Infectious Diseases          Eliakim-Raz, Noa; Rabin Medical Center, Beilinson Hospital, Unit of Infectious Diseases          Daikos, George; Laiko General Hospital, First Department of Propaedeutic Medicine          Skiada, Anna; University of Athens, First Department of Medicine          Antoniadou, Anastasia; University of Athens, Fourth Department of Medicine          Carmeli, Yehuda; Tel Aviv Sourasky Medical Centre, Division of Epidemiology and Preventive Medicine          Nutman, Amir; Tel Aviv Sourasky Medical Centre, Division of Epidemiology and Preventive Medicine          Levi, Inbar; Tel Aviv Sourasky Medical Centre, Division of Epidemiology and Preventive Medicine          Adler, Amos; Tel Aviv Sourasky Medical Centre, Microbiology Laboratory          Durante-Mangoni, Emanuele; Second University of Naples, Monaldi Hospital-AORN dei Colli, Internal Medicine          Andini, Roberto; Second University of Naples, Monaldi Hospital-AORN dei Colli, Internal Medicine          Cavezza, Giusi; Second University of Naples, Monaldi Hospital-AORN dei Colli, Internal Medicine          Mouton, Johan; Erasmus MC, Department of Medical Microbiology and Infectious Diseases          Wijma, Rixt; Erasmus MC, Department of Medical Microbiology and Infectious Diseases          Theuretzbacher, Ursula; Center for Anti-Infective Agents,          Friberg, Lena; Uppsala University, Department of Pharmaceutical Biosciences          Kristoffersson, Anders; Uppsala University, Department of Pharmaceutical Biosciences          Zusman, Oren; Rabin Medical Center          Koppel, Fidi; Rambam Health Care Campus          Dishon, Yael; Rambam Healthcare Campus, Division of Infectious Diseases          Altunin, Sergey; Rambam Healthcare Campus, Division of Infectious Diseases</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Diseases Paul, Mical; Rambam Healthcare Campus, Division of Infectious Diseases
<b>Primary Subject Heading:</b>	Infectious diseases
<b>Secondary Subject Heading:</b>	Pharmacology and therapeutics
<b>Keywords:</b>	colistin, combination therapy, meropenem, carbapenem-resistant Gram negative bacteria

For peer review only

SCHOLARONE™  
Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2015-009956 on 20 April 2016. Downloaded from <http://bmjopen.bmj.com/> on November 20, 2019 by guest. Protected by copyright.

1  
2  
3 **Multicenter open-label randomized controlled trial to compare**  
4 **colistin alone with colistin plus meropenem for the treatment of**  
5 **severe infections caused by carbapenem-resistant Gram-negative**  
6 **infections (AIDA): study protocol**  
7  
8  
9  
10  
11  
12  
13  
14  
15

16 **Author information:**

17 Yaakov Dickstein<sup>a</sup>, Leonard Leibovici<sup>b,c</sup>, Dafna Yahav<sup>c,d</sup>, Noa Eliakim-Raz<sup>c,d</sup>, George  
18 L. Daikos<sup>e</sup>, Anna Skiada<sup>e</sup>, Anastasia Antoniadou<sup>f</sup>, Yehuda Carmeli<sup>g</sup>, Amir Nutman<sup>c,g</sup>,  
19 Inbar Levi<sup>g</sup>, Amos Adler<sup>h</sup>, Emanuele Durante-Mangoni<sup>i</sup>, Roberto Andini<sup>i</sup>, Giusi  
20 Cavezza<sup>i</sup>, Johan W. Mouton<sup>j,k</sup>, Rixt A. Wijma<sup>j</sup>, Ursula Theuretzbacher<sup>l</sup>, Lena E.  
21 Friberg<sup>m</sup>, Anders N. Kristoffersson<sup>m</sup>, Oren Zusman<sup>b,c</sup>, Fidi Koppel<sup>a</sup>, Yael Dishon  
22 Benattar<sup>a</sup>, Sergey Altunin<sup>n,#</sup>, Mical Paul<sup>a,n</sup> and the AIDA consortium  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 Corresponding author: Prof. Mical Paul, Division of Infectious Diseases, Rambam  
34 Healthcare Campus, Haaliya Hashniya 8, Haifa, Israel, email [paulm@post.tau.ac.il](mailto:paulm@post.tau.ac.il),  
35 Tel: 04-7773376.  
36  
37  
38  
39  
40  
41

42 <sup>a</sup> Division of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel

43 <sup>b</sup> Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva,  
44 Israel  
45  
46  
47

48 <sup>c</sup> Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel

49 <sup>d</sup> Unit of Infectious Diseases, Rabin Medical Center, Beilinson Hospital, Petah Tikva,  
50 Israel  
51  
52  
53  
54

55 <sup>e</sup> First Department of Medicine, University of Athens, Athens, Greece

56 <sup>f</sup> Fourth Department of Medicine, University of Athens, Athens, Greece  
57  
58  
59  
60

<sup>g</sup> Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

<sup>h</sup> Microbiology Laboratory, Tel Aviv Sourasky Medical Centre, Tel-Aviv, Israel

<sup>i</sup> Internal Medicine, Second University of Naples, Monaldi Hospital-AORN dei Colli, Napoli, Italy

<sup>j</sup> Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands

<sup>k</sup> Department of Medical Microbiology, Radboudumc, Nijmegen, The Netherlands

<sup>l</sup> Center for Anti-Infective Agents, Vienna, Austria

<sup>m</sup> Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

<sup>n</sup> Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel

<sup>#</sup> deceased

**Key words:** Colistin, Combination therapy, Meropenem, Carbapenem-resistant Gram-negative bacteria

**Word count:** 4591

## ABSTRACT

**Introduction:** The emergence of antibiotic-resistant bacteria has driven renewed interest in older antibacterials, including colistin. Previous studies have shown that colistin is less effective than modern antibiotics and toxic. In-vitro synergy studies and clinical observational studies suggest a benefit of combining colistin with a carbapenem. A randomized controlled study is necessary for clarification.

**Methods and analysis:** This is a multicenter, investigator-initiated, open-label, randomized, controlled superiority 1:1 study comparing colistin monotherapy with colistin-meropenem combination therapy for infections caused by carbapenem-resistant Gram-negative bacteria. The study is being conducted in six centers in three countries (Italy, Greece and Israel). We include patients with hospital- and ventilator-associated pneumonia, blood-stream infections and urosepsis. The primary outcome is treatment success at day 14, defined as survival, hemodynamic stability, stable or improved respiratory status for pneumonia patients, microbiological cure for bacteremia patients and stability or improvement of the Sequential Organ Failure Assessment (SOFA) score. Secondary outcomes include 14- and 28-day mortality as well as other clinical endpoints and safety outcomes. A sample size of 360 patients was calculated based on an absolute improvement in clinical success of 15% with combination therapy. Outcomes will be assessed by intention-to-treat. Serum colistin samples are obtained from all patients to obtain population pharmacokinetic models. Microbiological sampling includes weekly surveillance samples with analysis of resistance mechanisms and synergy. An observational trial is evaluating patients who met eligibility requirements but were not randomized in order to assess generalizability of findings.

1  
2  
3 **Ethics and dissemination:** The study was approved by ethics committees at each  
4 center and informed consent will be obtained for all patients. The trial is being  
5 performed under the auspices of an independent data and safety monitoring  
6 committee and is included in a broad dissemination strategy regarding revival of old  
7 antibiotics.  
8  
9

10  
11  
12  
13  
14 **Trial registration:** This trial is registered with ClinicalTrials.gov (NCT01732250)  
15 and EudraCT (2012-004819-31).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## INTRODUCTION

### Background and rationale

Colistin, discovered in 1947, has resurged in the last decade for the treatment of multidrug-resistant Gram-negative bacteria (MDR GNB). As a polymyxin, it acts both by disrupting the cell membrane and by binding lipid polysaccharide and blocking the effects of endotoxin [1,2]. Polymyxins are bactericidal by inducing rapid cell death mediated through hydroxyl radical production [3]. Observational studies suggested higher mortality among patients treated with colistin or polymyxin B compared to patients given other antibiotics, mostly beta-lactams [4,5]. Despite the fact that most of these studies were limited by the probable underdosing of colistin, the pooled rates of nephrotoxicity were higher with colistin compared to other antibiotics [4]. Rates of nephrotoxicity in recent studies designed to assess this outcome have ranged from 6-14% to 32-55%, with much of the difference due to different definitions of renal failure [6,7,8,9,10,11,12,13,14,15]. Both the daily dose [12,15] and the total cumulative dose [10,11,16] have been associated with increased risk of nephrotoxicity. Additionally, colistin is associated with neurological toxicity that is more difficult to appreciate in critically-ill patients [17].

Studies currently focus on improving the efficacy and safety profile of colistin, combination therapy being one commonly adopted strategy. Ideally, a combination regimen should improve clinical success via improved reduction of the bacterial load, more rapid killing, killing or inhibition at lower drug concentrations thus avoiding toxicity and minimizing the risk of resistance selection. Carbapenems are commonly added to colistin in clinical practice for the treatment of infections due to carbapenem-resistant Gram-negative bacteria (CR GNB). Several recent observational studies

1  
2  
3 concluded that combination therapies including a carbapenem have a significant and  
4 important advantage over colistin monotherapy [18,19,20,21,22,23]. These studies  
5 have been highly influential on clinical practice worldwide, leading to the view that  
6 colistin should not be used as monotherapy. The limitations of these studies include  
7 indication bias inherent to observational studies comparing treatment regimens,  
8 moderate to very small sample sizes, inclusion of multiple different regimens in the  
9 combination arm and inclusion of carbapenemase-producing carbapenem-susceptible  
10 bacteria together with carbapenem-resistant bacteria [24].  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 To formally appraise the potential benefit of polymyxin-carbapenem combination  
24 therapy, we conducted a systematic review and meta-analysis of their in-vitro  
25 interactions [25]. We found that in time-kill studies, carbapenem-polymyxin  
26 combination therapy showed synergy rates of 77% (95% CI 64-87) for *A. baumannii*,  
27 44% (95% CI 23-51%) for *Klebsiella pneumoniae* and 50% (95% CI 30-69%) for  
28 *Pseudomonas aeruginosa* with low antagonism rates for all. For *A. baumannii*,  
29 meropenem was more synergistic than imipenem, whereas for *P. aeruginosa* the  
30 opposite was true. In studies on single isolates, the use of combination therapy led to  
31 less resistance development in-vitro. Higher synergy rates, observed more frequently  
32 with *A. baumannii* than with *K. pneumoniae* or *P. aeruginosa* strains, could have been  
33 related to lower MICs of *A. baumannii* to carbapenems in general. Differences  
34 between carbapenems were less clear and depended on bacteria type. The systematic  
35 review supported a biological rationale for a clinical trial, along with the selection of  
36 meropenem as the carbapenem of choice in order to maximize the advantage to  
37 combination therapy as *A. baumannii* is the dominant bacterium at the trial sites.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Learning from in-vitro studies on clinical effects is difficult because the bacterial  
4 inocula differ, drug levels may be affected by practical constraints of antibiotic  
5 administration and clinical effects are confounded by underlying conditions and  
6 adverse effects. Previous analyses have shown that despite strong in-vitro proof of  
7 synergy and prevention of resistance selection for beta-lactams and aminoglycosides,  
8 randomized controlled trials did not show a clinical benefit for the same combinations  
9 compared with beta-lactams alone in the treatment of sepsis [26,27,28]. Furthermore,  
10 the possibility of further resistance selection due to widespread carbapenem usage  
11 following adoption of combination therapy as a policy, increased toxicity and  
12 antagonistic interactions between antibiotics may render combination therapy worse  
13 than monotherapy and not merely non-inferior. Thus, despite in-vitro data supporting  
14 synergy between carbapenems and colistin, proof of improved clinical outcome is  
15 essential.

### 34 Objectives

36 Our study was born from the need to examine in an unbiased way whether  
37 combination therapy offers an advantage. To this end, a prospectively designed  
38 randomized controlled trial (RCT) methodology was chosen to enable strict  
39 definitions of the treatment regimens, optimal antibiotic dosing and schedule  
40 definitions and treatment assignment unrelated to infection or patient characteristics.  
41 The primary objective of the trial is to show superiority of colistin-meropenem  
42 combination therapy to colistin monotherapy in the treatment of patients infected with  
43 carbapenem-resistant GNB. A secondary objective is to obtain improved population  
44 pharmacokinetic models (PPM) for colistin.

## METHODS AND ANALYSIS

### Design

Multicenter, open label, 1:1 superiority randomized-controlled trial.

### Setting

The study is currently ongoing at Laikon and Attikon Hospitals in Athens, Greece; Tel Aviv Medical Center (Tel Aviv), Rabin Medical Center, Beilinson Hospital (Petah-Tikva) and Rambam Health Care Center (Haifa), Israel; and Monaldi Hospital, Naples, Italy. Recruitment began in October 2013 and is planned to continue until November 2016.

### Eligibility criteria

#### Inclusion criteria

We include adult inpatients  $\geq 18$  years with ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), urosepsis or bloodstream infections (BSI) of any source, as defined in Table 1, caused by carbapenem non-susceptible and colistin-susceptible Gram-negative bacteria, including *Acinetobacter* spp., *P. aeruginosa* or any Enterobacteriaceae (including but not limited to *K. pneumoniae*, *E. coli* and *Enterobacter* spp.). Patient recruitment occurs only after microbiological documentation, susceptibility testing and signed informed consent. Carbapenem non-susceptibility is defined using the EUCAST breakpoint of MIC  $> 2$  mg/L and colistin sensitivity as MIC  $\leq 2$  mg/L for *Acinetobacter* spp. and Enterobacteriaceae and  $\leq 4$  mg/L for *Pseudomonas* spp. We include patients with infections caused by bacteria susceptible to sulbactam, tetracyclines, tigecycline, cotrimoxazole or aminoglycosides as we consider that these are not established treatments for severe Gram-negative infections nor has their superiority to colistin been established. We permit the

inclusion of patients with polymicrobial infections where all Gram-negative isolates are carbapenem non-susceptible, or mixed with Gram-positive bacteria or anaerobes (see permitted additional antibiotics below). Inclusion is based on the testing performed in individual study hospitals after mapping the acceptability of the methods used in participating hospitals. Isolate identification and carbapenem MICs are confirmed in a central laboratory.

**Table 1: Inclusion Criteria for Infections**

Type of infection	Definition
Bloodstream infection (BSI)	Growth of the relevant bacteria in one or more blood culture bottles accompanied by the systemic inflammatory response syndrome (SIRS) within 48h of blood culture taken time. BSIs can be either primary or secondary to any other source of infection.
Ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HAP)	<p>Pneumonia fulfilling CDC/NHSN surveillance definition of health care-associated infection for pneumonia with specific laboratory findings (PNU2) with modifications to the laboratory criteria [29]. Ventilator-associated pneumonia will be defined in persons who had a device to assist or control respiration continuously through a tracheostomy or by endotracheal intubation within the 48-hour period before the onset of infection. BAL will not be performed routinely for the purposes of the trial. The specific criteria required for diagnosis of pneumonia will be all of the following:</p> <ol style="list-style-type: none"> <li>1. Chest radiograph with new or progressive and persistent infiltrate, consolidation or cavitation.</li> <li>2. At least 1 of the following signs of sepsis: Fever <math>&gt;38^{\circ}\text{C}</math> with no other recognized cause; Leukopenia <math>&lt;4000</math> WBC/mm<sup>3</sup> or leukocytosis <math>&gt;12,000</math> WBC/mm<sup>3</sup>; For adults <math>&gt;70</math> years old, altered mental status with no other recognized cause</li> <li>3. At least 1 of the following respiratory signs/symptoms: New onset of purulent sputum or change in character of sputum or increased respiratory secretions or increased suctioning requirements; New onset or worsening cough or dyspnea or tachypnea <math>&gt;25</math> breaths per minute; Rales or bronchial breath sounds; Worsening gas exchange, including O<sub>2</sub> desaturations, PaO<sub>2</sub>/FiO<sub>2</sub> <math>&lt;240</math>, or increased oxygen requirements</li> <li>4. Laboratory criterion: Growth of the relevant bacteria in culture of sputum, tracheal aspirate, bronchoalveolar lavage or protected specimen brushing. For any lower respiratory secretion other than bronchoalveolar lavage (BAL) or protected specimen brush (PSB), the respiratory sample has to contain <math>&gt;25</math> neutrophils and <math>&lt;10</math> squamous epithelial cells per low power field, identified by Gram stain</li> </ol>
Probable ventilator-associated pneumonia (VAP)	Pneumonia fulfilling CDC/NHSN 2013 revised surveillance definition, omitting the criterion of antimicrobial treatment before randomization and modifying the

	microbiological criteria [30]: <ol style="list-style-type: none"> <li>1. Mechanical ventilation for <math>\geq 3</math> calendar days</li> <li>2. Worsening oxygenation, following <math>\geq 2</math> calendar days of stable or decreasing FiO<sub>2</sub> or PEEP, presenting as:             <ul style="list-style-type: none"> <li>○ Minimum daily FiO<sub>2</sub> values increase <math>\geq 0.20</math> (20 points) over baseline and remain at or above that increased level for <math>\geq 2</math> calendar days OR</li> <li>○ Minimum daily PEEP values increase <math>\geq 3</math> cmH<sub>2</sub>O over baseline and remain at or above that increased level for <math>\geq 2</math> calendar days.</li> </ul> </li> <li>3. Temperature <math>&gt; 38^\circ\text{C}</math> or <math>&lt; 36^\circ\text{C}</math>, OR white blood cell count <math>\geq 12,000</math> cells/mm<sup>3</sup> or <math>\leq 4,000</math> cells/mm<sup>3</sup></li> <li>4. Purulent respiratory secretions AND positive respiratory culture; OR positive culture of pleural fluid. For any lower respiratory secretion other than bronchoalveolar lavage (BAL) or protected specimen brush (PSB), the respiratory sample has to contain <math>&gt;25</math> neutrophils and <math>&lt;10</math> squamous epithelial cells per low power field, identified by Gram stain.</li> </ol>
Urosepsis	Positive urine culture with relevant bacteria $\geq 10^5$ CFU/ml with pyuria, accompanied by the systemic inflammatory response syndrome (SIRS) within 48h of taken time and no other explanation for SIRS

#### Exclusion criteria

We exclude patients treated with colistin for more than 96 hours prior to randomization, but encourage all efforts to recruit patients as soon as possible after identification. The relatively long time period permitted for effective treatment prior to study enrollment was defined to allow maximal patient inclusion in hospitals using colistin empirically and for patients identified during weekends and holidays. We exclude infections when the CR isolate is susceptible to quinolones or any beta-lactam. Similarly, we exclude patients with polymicrobial infections where one or more of the clinically-significant Gram-negative bacteria are susceptible to any beta-lactam as we do not consider it appropriate to treat a beta-lactam-susceptible Gram-negative bacterium with colistin monotherapy given the data available from observational studies on colistin's inferiority to beta-lactams. In addition, we exclude patients in whom informed consent cannot be obtained, those who were previously enrolled in the trial, pregnant women and those with a known allergy to colistin or

1  
2  
3 carbapenems. Pregnancy testing is not performed routinely in fertile women not  
4  
5 known to be pregnant for the purposes of the trial. Originally, we excluded all patients  
6  
7 with seizures because of the fear of inducing seizures with high-dose meropenem.  
8  
9 Subsequently, we introduced an amendment to exclude only those who have a history  
10  
11 of prior carbapenem-induced seizures and epileptic patients requiring chronic  
12  
13 antiepileptic treatment unless treated previously with a carbapenem for more than 48  
14  
15 hours without experiencing a seizure. The amendment was supported by clinical  
16  
17 practice in the study centers when treating other patients at risk for carbapenem-  
18  
19 induced seizures.  
20  
21

## 22 23 24 25 **Interventions**

26  
27 At the time of the protocol design, pharmacokinetic (PK) studies demonstrated that it  
28  
29 takes about 36-48 hours for colistin to reach therapeutic concentrations in plasma ( $\geq 2$   
30  
31 mg/L) using classical dosing in patients with normal renal function [31,32]. Thus, a  
32  
33 loading dose equal to the approximate total daily dose was suggested [33].  
34  
35

36 Furthermore, these studies demonstrated that once or twice daily dosing is probably  
37  
38 sufficient. We tailored the colistin administration regimen in the trial according to  
39  
40 these data [34].  
41  
42

## 43 44 45 **Colistin arm**

46  
47 Patients receive a loading dose of 9 MIU, regardless of renal function. For patients  
48  
49 with normal renal function ( $\text{CrCl} \geq 50$  ml/min), the loading dose is followed by 4.5  
50  
51 MIU q12hr [32,35] beginning 12 hrs. after the loading dose. Colistin is administered  
52  
53 as a 30 minute intravenous infusion. Patients treated with colistin before  
54  
55 randomization are given a loading dose if treated for <48 hours without a loading  
56  
57  
58  
59  
60

dose at the start of treatment. Patients who previously received a loading dose or who have been treated for 48 hours or more continue colistin without a loading dose, using the trial schedule. Maintenance dose adjustment for patients with renal failure is based on the study by Garoznik et al. [31] aiming to achieve a colistin steady state average level of 2-2.5 mg/L (Table 2). No dosage adjustments are performed for hepatic insufficiency.

**Table 2: Drug dosing schedule**

Renal function	Colistin maintenance dose <sup>1</sup>	Meropenem dosing
CrCl $\geq$ 50 ml/min <sup>2</sup>	4.5 MIU q12h	2 gr q8hr
CrCl <50 ml/min, without renal replacement therapy	Total daily dose in MIU = $[2*(1.5*CrCl + 30)]/30$	CrCl 26-50 ml-min: 2 gr q12hr CrCl 10-25 ml/min: 1 gr q12hr
Continuous renal replacement therapy	Fixed dose of 6 MIU q12h	1 gr q12hr
Intermittent hemodialysis	1 MIU q12h, with a 1 MIU supplemental dose after dialysis	1 gr q24hr with a supplemental dose given after dialysis

<sup>1</sup> All patients receive a loading dose of 9MIU regardless of renal function. Adjustment refers only to the maintenance dose started 12 hrs. after the loading dose

<sup>2</sup> CrCl should be expressed in ml/min/1.73 m<sup>2</sup>, using the MDRD formula, Cockcroft and Gault equation or other means.

Colistin + meropenem arm

Colistin is administered as above and combined with IV meropenem 2gr q8hr for patients with normal renal function (CrCl>50 ml/min). Meropenem is administered as a prolonged infusion over 3 hr. For patients with impaired renal function, dosing is



1  
2  
3 adjusted (Table 2) without a change in the infusion time [36]. No dosage adjustments  
4  
5 are performed for hepatic insufficiency.  
6  
7

8  
9  
10 For both treatment arms, the recommended duration of antibiotic treatment is at least  
11  
12 10 days for all listed indications. If infectious complications mandate longer  
13  
14 treatment, duration is prolonged as appropriate. We permit the concomitant  
15  
16 administration of the following antibiotics for polymicrobial infections: vancomycin,  
17  
18 oxacillin derivatives, cefazolin, ampicillin, penicillin or metronidazole. We do not  
19  
20 permit the routine addition of rifampin, tigecycline, minocycline, aminoglycosides or  
21  
22 colistin inhalations.  
23  
24

## 25 26 27 **Outcomes**

28  
29 The primary outcome is treatment success measured at 14 days from randomization.  
30  
31 Success is defined as a composite of survival; hemodynamic stability; stable or  
32  
33 improved respiratory status for patients with pneumonia; microbiological cure for  
34  
35 patients with bacteremia; and stability or improvement of the Sequential Organ  
36  
37 Failure Assessment (SOFA) score (Table 3). Treatment failure is defined as failure to  
38  
39 meet any of the composite criteria on day 14. The outcome was defined by consensus  
40  
41 of the investigators addressing clinically relevant outcome measures among critically-  
42  
43 ill patients and after reviewing published outcome definitions for HAP/VAP [37] and  
44  
45 FDA and EMA guidance on the design of clinical trials of antibacterials [38].  
46  
47

48  
49 Secondary outcomes include 14 and 28-day all-cause mortality; clinical success  
50  
51 without modification of the assigned antibiotic regimen; time to defervescence; time  
52  
53 to weaning from mechanical ventilation in VAP; time to hospital discharge; change in  
54  
55 functional capacity; microbiological failure; superinfections; colonization by CR or  
56  
57  
58  
59  
60

colistin-resistant bacteria; CDAD; renal failure; seizures and other adverse events.

Outcome definitions are provided in Table 3.

**Table 3: Outcomes**

Outcome	Definition
Clinical success (primary outcome)	Composite of: <ul style="list-style-type: none"> <li>• Patient alive</li> <li>• Systolic blood pressure &gt;90 mmHg without need for vasopressor support</li> <li>• Stable or improved SOFA score, defined as:               <ul style="list-style-type: none"> <li>○ for baseline SOFA <math>\geq</math> 3: a decrease of at least 30%;</li> <li>○ for baseline SOFA &lt;3: stable or decreased SOFA score</li> </ul> </li> <li>• For patients with HAP/VAP, PaO<sub>2</sub>/FiO<sub>2</sub> ratio stable or improved</li> <li>• For patients with bacteremia, no growth of the initial isolate in blood cultures taken on day 14 if patient still febrile</li> </ul>
14-day all-cause mortality	
28-day all-cause mortality	
Clinical success without modification	Clinical success, as defined above, but any modification to the antibiotic treatment not permitted by protocol will also be considered as failure. This will include any change or addition of antibiotics not permitted by study protocol during the first 10 days after randomization. Early discontinuation of antibiotic treatment will not be considered as failure.
Time to defervescence	Time to reach a temperature of <38°C with no recurrence for 3 days
Time to weaning from mechanical ventilation	Days from randomization to weaning for patients with VAP weaned alive
Time to hospital discharge	Days to hospital discharge among patients discharged alive
Change in functional capacity	Assessed from baseline status before infection onset to discharge from hospital Function capacity will be classified into 3 grades: <ol style="list-style-type: none"> <li>1. Independent</li> <li>2. Need for assistance for activities of daily living</li> <li>3. Bedridden</li> </ol>
Microbiological failure	Isolation of the initial isolate (phenotypically identical) in a clinical sample (blood or other) 7 days or more after start of treatment or its identification in respiratory samples. (see Data collection and microbiological sampling and Table 4, below)
Superinfection	New clinically or microbiologically-documented infections by CDC criteria within 28 days, any and specifically those caused by newly-acquired carbapenem-resistant or colistin-resistant Gram-negative bacteria.
Resistant colonization	Colonization by phenotypically newly-acquired carbapenem-resistant or colistin-resistant Gram-negative bacteria. Assessed by rectal surveillance (see Data collection and microbiological sampling and Table 4, below)
CDAD	Diarrhea with a positive <i>C. difficile</i> toxin test
Renal failure	Renal failure using the RIFLE criteria [39] at day 14 and day 28 relative to the day

	of randomization.
Seizures	Seizures or other neurological adverse events including critical illness neuropathy
Other adverse events	Requiring treatment discontinuation

### PK assessment

Two blood samples for colistin levels are obtained from all patients included in the trial. The 1<sup>st</sup> sample is obtained 15 min. after the end of the loading dose (45 min. from its start). The 2<sup>nd</sup> sample is obtained 10 hrs. after the 2<sup>nd</sup> colistin dose (22 hrs. from the start of the loading dose). For patients treated with colistin before randomization, samples are taken 15 min. following the first post-randomization dose and 2 hrs. prior to the third. This sparse sampling strategy was deemed to provide the optimal information on individual colistin exposure based on practical constraints, previous modeling of colistin PK [32, 35] and the optimal design methodology [40]. Meropenem concentrations are determined using the same samples for those patients receiving combination therapy. Plasma samples are frozen immediately at the study centers and sent for analysis of colistin levels at a central laboratory in Uppsala University, Sweden and from there to Erasmus MC for assessment of meropenem concentrations where applicable.

### Participant timeline

All patients are followed up to 28 days following enrollment in the trial. For hospitalized patients, follow-up is performed on a regular basis through study visits (Table 4) and daily through patients' records. For the rare instances in which patients are discharged before day 28, follow-up is completed via the appropriate healthcare system databases.

**Table 4: Participant timeline for RCT**

Day	Enrollment and randomization	Background and clinical information	Colistin levels	Clinical follow-up	Outcome data	Rectal surveillance swabs	Blood cultures if febrile	Other microbiological sampling <sup>1</sup>
1	X	X	X	X		X		X
2			X	X			X	
5				X			X	
7				X	X	X	X	X
9							X	
10							X	
14				X	X	X	X	
21						X		
28				X	X	X		

<sup>1</sup> Index culture on day 1 (randomization); Sputum culture for patients with HAP/VAP and urine culture for patients with urosepsis patients on day 7

### Sample size

The expected mortality in our trial cohort is approximately 30%, based on previous studies [41,42,43]. A re-analysis of a cohort study by the researchers indicated a 55% treatment success rate using our primary composite outcome definitions [5]. To show an improvement in treatment success (primary outcome) from 55% with colistin alone to 70% with combination therapy with a 1:1 randomization ratio, a sample of 324 patients (162 per group) was deemed necessary (uncorrected chi-squared test, alpha=0.05, power=0.8, PS Power and Sample Size Calculations). Assuming a non-evaluability rate of about 10%, we plan to recruit 360 patients.

### Patient identification, randomization and blinding

Potential patients are identified through daily or twice-daily reports on carbapenem-resistant isolates from blood, urine and sputum samples from the microbiology laboratory. After determining whether patients fulfill inclusion and exclusion criteria, randomization is performed by investigators from the respective centers. Central randomization is performed using a custom-built web application, using randomized permuted blocks of varying length, stratified by center. The first block in each strata

1  
2  
3 begins at a random position [44]. Each randomization attempt requires entry of a  
4  
5 matching unique ID from the Epi-Info case report form generated when entering  
6  
7 patients' eligibility (CRF; see below, data collection), and each randomization attempt  
8  
9 is logged. No blinding is used after randomization. Outcome adjudication will be  
10  
11 performed centrally blinded to the assigned intervention using the clinical data  
12  
13 collected by individual-center investigators.  
14  
15

### 16 17 18 **Data collection and microbiological sampling**

19  
20 We designed a case report form using the Epi-Info free software package  
21  
22 (<http://wwwn.cdc.gov/epiinfo/>). A database is kept at each site, from which  
23  
24 anonymized data are exported periodically and sent to the primary investigator. See  
25  
26 Table 5 for a list of the data collected and participant timeline above. For assessment  
27  
28 of microbiological response, synergy and resistance development we obtain (in  
29  
30 addition to the index culture defined for trial inclusion) a sample from the primary  
31  
32 source of isolation of the CRGNB on day 7 (sputum for HAP/VAP patients and urine  
33  
34 for patients with urosepsis) and rectal swabs for CRGNBs isolation on days 1,7,14  
35  
36 and 28; samples are collected from all patients. Blood cultures are repeated every 48  
37  
38 hrs. as long as the patient is febrile. Treating physicians will be permitted to obtain  
39  
40 other samples at their own discretion. The index isolate as well as all phenotypically-  
41  
42 identical repeat isolates are kept for further analyses. Samples are frozen and analyzed  
43  
44 centrally at Tel-Aviv Medical Center in Israel.  
45  
46  
47  
48  
49  
50

51 **Table 5: Data Collected for RCT Patients**

- |  |
|--|
| <ul style="list-style-type: none"><li>52 • Patient demographics</li><li>53 • Background conditions, including the revised Charlson comorbidity index [45] and McCabe score</li><li>54 • Source of infection and diagnostic criteria for VAP and HAP including type of respiratory</li><li>55 specimen used for patient classification</li><li>56</li><li>57</li><li>58</li><li>59</li><li>60</li></ul> |
|--|

- Devices present at infection onset and risk factors for MDR colonization and infection
- Antibiotic treatment prior to onset of the infectious episode, empirical antibiotic treatment and all antibiotics used from randomization until day 28. We will document colistin administration times.
- Concomitant nephrotoxic agents: aminoglycosides, IV contrast material, cyclosporine
- Therapeutic procedures throughout the infectious episode (surgery, catheter extraction, etc.)
- Use of colistin inhalation therapy
- SOFA score
- All outcomes as defined

### Concomitant observational study

Previous studies have found that the patients included in randomized controlled trials of antibiotics differ significantly from patients encountered in clinical practice, particularly amongst the critically ill [46,47]. This difference threatens the external validity and therefore the generalizability of the findings in these trials. In order to examine the external validity of the present trial and to provide an observational comparison between the trial treatment regimens in the overall cohort, we are collecting all clinical data and treatment regimens from patients not included in the RCT for the reasons detailed in Table 6 but otherwise fulfilling clinical and microbiological inclusion criteria. Treatment in this arm is based on attending physicians' decisions. Clinical and microbiological samples for these patients are collected only for routine purposes and are neither kept nor analyzed as for the main trial. Data are kept anonymously. Informed consent for data collection is not required, as no intervention is planned.

### Table 6: Eligibility Criteria for Observational Study

- Unable to provide informed consent or otherwise no informed consent
- Identified later than 96h after start of treatment

- Second and subsequent episodes of infection for patients included in the RCT. A separate episode of infection will be defined as an infection occurring at least 28 days after the index episode of infection and separated by at least 7 days of antibiotics.

### Statistical analysis

The primary analysis will be by intention-to-treat for all randomized patients by their treatment assignment. A secondary analysis, per protocol, will be defined for patients surviving at least 48 hrs. and receiving at least 5 days of the assigned antibiotic regimen (type and dose) or until death if death occurs between days 3-5, without concomitant antibiotics active against the CR-GNB. Predefined subgroup analyses for the primary and mortality outcomes include:

- Patients who did not receive covering antibiotic treatment in the first 48 hours after culture taken date (patients receiving inappropriate empirical antibiotic treatment)
- Patients with VAP/HAP or bacteremia (excluding probable VAP and urosepsis)
- Patients in whom the infecting bacteria has an MIC to meropenem <16 mg/L

Baseline characteristics and outcomes of the study groups will be compared.

Significance will be set at  $p < 0.05$  and all tests will be 2-sided. Time-to-event outcomes will be assessed using survival analysis. We will conduct a multivariable analysis of the randomized cohort and the randomized + observational cohorts (see below), to examine the independent effect of the study regimen on 28-day mortality.

A pharmacokinetic/pharmacodynamic (PK/PD) analysis is also planned, using the same outcomes, but PK/PD parameter estimates of individual patients as exploratory variables.

### Data and safety monitoring

The present trial is part of the larger AIDA project which is designed to assess the efficacy and safety of old, revived antibiotics in the treatment of infections with antibiotic-resistant bacteria. As such, the trial is being performed under the auspices of the data and safety monitoring committee (DSMC) of the AIDA project which is independent of the organizers of both the study and the AIDA project. The DSMC has full access to trial data for review. In addition, there will be three yearly evaluations over the course of the trial at which a summary of trial procedures to date will be presented.

Both antibiotics studies have long been in use, meropenem's adverse event profile is known and we do not expect specific adverse events related to the interaction between colistin and meropenem. The main concerns with combination therapy relative to colistin monotherapy is resistance development and *Clostridium difficile* infection.

We will monitor both, addressing resistance development through the search for and documentation of colonization and clinical infections with new CR GNBs and any colistin-resistant GNBs.

No interim analyses are planned. In our trial, the risks that the trial arm (combination therapy) is associated with significantly better or worse outcomes than the control arm (monotherapy) such that an interim analysis would lead to early stopping were assessed as low.

### ETHICS AND DISSEMINATION

The study was approved by the ethics committees at each participating center and informed consent is obtained for all patients. In Italy and Greece a relative is an



1  
2  
3 acceptable surrogate for patients unable to provide informed consent. In Israel,  
4  
5 consent from a legal guardian or an independent physician (providing direct patient  
6  
7 care but not participating in the study) are acceptable, the latter since the study was  
8  
9 approved as “emergency research”.

10  
11  
12  
13  
14 The trial was registered with the National Institutes of Health (NIH) trial registry  
15  
16 (NCT01732250; registered on 19 November 2012) and European Union Drug  
17  
18 Regulating Authorities Clinical Trials (EudraCT) registry (2013-005583-25;  
19  
20 registered on 8 July 2013) before the start of the trial.  
21  
22  
23

24  
25 The study investigators pioneered a coordinated initiative to “re-develop” old, now  
26  
27 resurgent antibiotics that have never been analyzed in a structured process for drug  
28  
29 assessment and regulatory approval meeting current scientific standards. We  
30  
31 organised an international conference to raise broad awareness and addressed the need  
32  
33 for a structured process to fill the knowledge gaps for old revived antibiotics [48]. A  
34  
35 series of publications highlighted a range of topics regarding old antibiotics  
36  
37 [49,50,51,52,53,54]. Similarly, study investigators actively participated in the 1<sup>st</sup> and  
38  
39 2<sup>nd</sup> international polymyxin conferences, where the study protocol and progress were  
40  
41 discussed [55]. A range of dissemination activities are planned or ongoing, including  
42  
43 educational courses dedicated to advances in optimizing the use of colistin and other  
44  
45 revived antibiotics as well as presentations and educational workshops at international  
46  
47 conferences. Ongoing PK analyses, an integral part of the colistin study, are being  
48  
49 presented at international conferences. We will publish the final report of the study.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

The present trial is part of the larger AIDA project ([www.aida-project.eu](http://www.aida-project.eu)) which has been designed to analyze the clinical effectiveness and optimal dosing of older antibiotics, including colistin, fosfomycin, nitrofurantoin, minocyclin and rifampicin (see [www.aida-project.eu](http://www.aida-project.eu)). Within this wider framework two further randomized-controlled trials are underway as well as a series of linked microbiological and PK/PD studies. The linked microbiological study of our trial will examine the effect of treatment regimen on density of resistant strains and the co-carriage of various carbapenem-resistant strains. Co-carried resistant strains belonging to different species and newly-acquired resistant strains will be further studied for mechanisms of resistance. An analysis is planned to examine correlations between carbapenem MICs, colistin MICs, molecular typing, mechanisms of resistance and synergy studies with treatment outcomes including clinical success, microbiological failure, and emergence of resistance. PK studies completed after the launch of our trial challenge the need for a loading dose [56]. We hope that new PK data generated on a large sample of patients during the course of the present trial will help to provide a definitive answer. In the linked PK/PD study we plan to improve population pharmacokinetic models (PPM) for colistin, predict exposures in individual patients using PPM and in the population by Monte Carlo simulations, correlate exposures with outcomes (efficacy and emergence of drug resistance) for colistin monotherapy vs. combination therapy and determine cut-offs of pharmacodynamic indices using Classification and Regression Tree (CART) analysis and logistic regression analysis, determine target exposures for each drug and combinations in preclinical models and suggest clinical breakpoints.

1  
2  
3  
4  
5 A concurrent NIH-funded randomized controlled trial is being conducted in the US,  
6  
7 assessing similar interventions and using comparable microbiological methods  
8  
9 (NCT01597973). An agreement has been reached between the NIH trial and the  
10  
11 present trials' primary investigators to examine possible collaboration. We are trying  
12  
13 to ensure comparability between the current and the NIH trial, in particular with  
14  
15 respect to the outcomes assessed to allow for comparison and compilation of results  
16  
17 after analysis of the current trial. We will pool results using methods of individual  
18  
19 patient level meta-analysis.  
20  
21  
22  
23

24  
25 Antibiotic approval trials are predominantly indication-based, focusing on a single  
26  
27 indication such as VAP, complicated UTI, etc. Our trial is pathogen-based,  
28  
29 comprising a spectrum of infections that are caused by carbapenem-resistant Gram-  
30  
31 negative bacteria and for which colistin is utilized. Though our trial design is focused  
32  
33 on practicability and on mirroring clinical practice, it may offer valuable experience  
34  
35 for future pathogen-directed designs in critically ill patients that need to meet  
36  
37 regulatory requirements based on EMA's 2013 guideline. A problem may arise in  
38  
39 trials focusing on pathogens if treatment effects differ significantly for different sites  
40  
41 of infection. PK models of different infection sites as well as pooling results with the  
42  
43 NIH trial to allow for subgroup analyses by types of infections may support the  
44  
45 validity of the results of a pathogen-focused trial. Outcomes defined for indication  
46  
47 based trials were inadequate for our trial. We sought an outcome that would reflect a  
48  
49 clinically-significant benefit for critically-ill patients, recognizing that survival is a  
50  
51 key outcome in this population. The proximity to randomization (14-day outcome as  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 currently recommended for severe infections) increases the chances that mortality is  
4 related to the infection and its treatment.  
5  
6  
7  
8

9  
10 During the process of obtaining approval for this trial at the participating sites, it  
11 became clear that numerous differences exist between the regulatory requirements of  
12 the countries involved. Amongst these is the approach to informed consent in  
13 incapacitated patients, as nearly all patients included in our trial. The Declaration of  
14 Helsinki states "For a potential research subject who is incapable of giving informed  
15 consent, the physician must seek informed consent from the legally authorised  
16 representative" [57]. In most countries involved in the present study a relative is an  
17 acceptable surrogate which renders clinical trials among incompetent patients  
18 feasible. At the Israeli sites on the other hand, the representative must be someone  
19 with court-appointed power of attorney over the patient's person. The European  
20 countries participating in the trial had no mechanisms in place to provide for patients  
21 who cannot provide consent and for whom a representative is lacking. In Israel, the  
22 study was approved under the label of "emergency research" allowing an independent  
23 physician to provide consent of incapacitated patients. Such an approval is granted for  
24 trials in which (1) the patient is in an immediate life-threatening condition, existing  
25 treatments are unsatisfactory, it is important to define optimal treatment for the  
26 condition and the study could not have been performed had informed consent been  
27 required; (2) the patient's life-threatening condition requires treatment and pre-  
28 clinical studies point in favor of the intervention assessed; (3) it is impossible to  
29 obtain informed consent from the patient because of the acute condition and treatment  
30 has to be provided in a time-window that does not allow assigning a legal guardian.  
31  
32 The researcher is obliged to request informed consent from the patient once the acute  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 condition is reversed and it is mandated that an independent data monitoring and  
4  
5 safety committee and the ethics committee follow the trial.  
6  
7  
8

9  
10 The implications of the differences between countries are ethical, methodological and  
11  
12 practical. Certainly it is desirable that the patient's medical surrogate have the  
13  
14 patient's best interests at heart as well as share common values with the patient  
15  
16 regarding issues related to medical decision-making. While the precise genealogical  
17  
18 relationship between two individuals is not a guarantor of these ideals, a system needs  
19  
20 to be in place to ensure them. Although the law could automatically label any relative  
21  
22 as having decision-making power, thus giving them the qualification of "legally  
23  
24 authorized representative", such a practice may be ethically questionable. The  
25  
26 provision of a legal framework for recruiting incapacitated patients without decision-  
27  
28 makers is ethically sound since it allows for these patients to potentially benefit from  
29  
30 experimental treatments. Lack of a framework on the other hand effectively excludes  
31  
32 their participation, denying any possible benefits. Methodologically, it biases studies  
33  
34 towards less severely-ill patients, thus denying not only current patients the potential  
35  
36 benefits of new therapies but also leading to uncertainty regarding their costs and  
37  
38 benefits in similar patients in the future. Finally, on a practical level it makes it more  
39  
40 difficult for researchers to conduct studies on the populations most in need of new  
41  
42 therapeutics, such as our study. We claimed that antibiotic treatment for severe  
43  
44 infections such as bacteremia and VAP caused by CRGNB fulfill all criteria for  
45  
46 emergency research. The FDA has a similar mechanism for emergency research and  
47  
48 we propose that future trials conducted among patients with severe infections caused  
49  
50 by carbapenem-resistant Gram-negative bacteria be approved under this clause.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## TRIAL STATUS

To date 240 patients, or 67% of the planned total, have been recruited within 25 months (of a planned 36), including 178 in Israel, 40 in Greece and 22 in Italy. The center in Italy began participation more than a year after trial commencement. An additional 204 patients (175 in Israel, 27 in Greece and 2 in Italy) have been recruited into the observational trial.

## AUTHORS' CONTRIBUTIONS

Conception, design, trial management and planned data analysis – JWM, LL, GD, YC, UT, MP, LF, AS, YC, AA, RAW, EDM, ANK

Trial database and randomization site design – JWM, OZ, AA, MP

Data collection – EDM, RA, GC, NER, DY, OZ, YD, AS, AA, IL, FK, YDB, SA, MP

Drug level assessment and analysis – JWM, LF, RAW

Microbiological analysis – JWM, YC, AA

Dissemination – UT

Wrote the first draft of the manuscript – YD, MP

Revised the protocol critically for important intellectual content and approved the final manuscript – all authors

Note: between the writing of the manuscript and final revisions, Sergey Altunin passed away unexpectedly. He will be missed.

## FUNDING

This work was supported by the European Commission FP7 AIDA project (Preserving old antibiotics for the future, Health-F3-2011-278348).

## COMPETING INTERESTS

The authors declare that they have no competing interests.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Zhang L, Dhillon P, Yan H, et al. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2000;44:3317-21.
2. Hughes B, Madan BR, Parratt JR. Polymyxin B sulphate protects cats against the haemodynamic and metabolic effects of *E. coli* endotoxin. *Br J Pharmacol* 1981;74:701-7.
3. Sampson TR, Liu X, Schroeder MR, et al. Rapid killing of *Acinetobacter baumannii* by polymyxins is mediated by a hydroxyl radical death pathway. *Antimicrob Agents Chemother* 2012;56:5642-9.
4. Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic. *Clin Microbiol Infect* 2012;18:18-29.
5. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. *J Antimicrob Chemother* 2010;65:1019-27.
6. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. *BMC Infect Dis* 2005;5:1.
7. Falagas ME, Kasiakou SK, Kofteridis DP, et al. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. *Eur J Clin Microbiol Infect Dis* 2006;25:596-9.
8. Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. *J Infect* 2008;56:185-90.
9. Cheng CY, Sheng WH, Wang JT, et al. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. *Int J Antimicrob Agents* 2010;35:297-300.
10. Falagas ME, Fragoulis KN, Kasiakou SK, et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. *Int J Antimicrob Agents* 2005;26:504-7.
11. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. *Clin Infect Disease* 2009;48:1724-8.



12. Deryke CA, Crawford AJ, Uddin N, et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. *Antimicrob Agents Chemother* 2010;54:4503-5.
13. Kim J, Lee KH, Yoo S, et al. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. *Int J Antimicrob Agents* 2009;34:434-8.
14. Ko H, Jeon M, Choo E, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. *Nephron Clin Pract* 2011;117:c284-8.
15. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. *J Infect* 2011;62:187-90.
16. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. *Ann Intern Med* 1970;72:857-68.
17. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. *Crit Care* 2006;10:R27.
18. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing *Klebsiella pneumoniae*: superiority of combination antimicrobial regimens. *Antimicrob Agents Chemother* 2012;56:2108-13.
19. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: importance of combination therapy. *Clin Infect Dis* 2012;55:943-50.
20. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant *Acinetobacter baumannii* bloodstream infections. *Eur J Clin Microbiol Infect Dis* 2014;33:1311-22.
21. Daikos GL, Tsaousi S, Tzouveleki LS, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. *Antimicrob Agents Chemother* 2014;58:2322-8.
22. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study. *J Antimicrob Chemother* 2015;70:2133-43.

- 1  
2  
3 23. Rigatto MH, Vieira FJ, Antochévis LC, et al. Polymyxin B in combination  
4 with in vitro non-susceptible antimicrobials versus polymyxin B in  
5 monotherapy in critically ill patients with *Acinetobacter baumannii* or  
6 *Pseudomonas aeruginosa* infections. *Antimicrob Agents Chemother* Published  
7 Online First: 10 August 2015. pii:AAC.00494-15.
- 8  
9  
10  
11 24. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for  
12 carbapenem-resistant Gram-negative bacteria. *J Antimicrob Chemother*  
13 2014;69:2305-9.
- 14  
15  
16 25. Zusman A, Avni T, Leibovici L, et al. Systematic review and meta-analysis of  
17 in vitro synergy of polymyxins and carbapenems. *Antimicrob Agents*  
18 *Chemother* 2013;57:5104-11.
- 19  
20  
21 26. Marcus R, Paul M, Elphick H, et al. Clinical implications of beta-lactam-  
22 aminoglycoside synergism: systematic review of randomised trials. *Int J*  
23 *Antimicrob Agents* 2011;37:491-503.
- 24  
25  
26 27. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta  
27 lactam-aminoglycoside combination therapy for fever with neutropenia:  
28 systematic review and meta-analysis. *BMJ* 2003;326:1111.
- 29  
30  
31 28. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy  
32 versus beta lactam-aminoglycoside combination therapy for sepsis in  
33 immunocompetent patients: systematic review and meta-analysis of  
34 randomised trials. *BMJ* 2004;328:668.
- 35  
36  
37 29. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of  
38 health care-associated infection and criteria for specific types of infections in  
39 the acute care setting. *Am J Infect Control* 2008;36:309-32.
- 40  
41  
42  
43 30. Centers for Disease Control and Prevention (CDC). Improving Surveillance  
44 for Ventilator-Associated Events in Adults 2012.  
45 [www.cdc.gov/nhsn/PDFs/vae/CDC\\_VAE\\_CommunicationsSummary-for-](http://www.cdc.gov/nhsn/PDFs/vae/CDC_VAE_CommunicationsSummary-for-compliance_20120313.pdf)  
46 [compliance\\_20120313.pdf](http://www.cdc.gov/nhsn/PDFs/vae/CDC_VAE_CommunicationsSummary-for-compliance_20120313.pdf). Accessed 22 July 2015.
- 47  
48  
49 31. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, et al. Population  
50 pharmacokinetics of colistin methanesulfonate and formed colistin in critically  
51 ill patients from a multicenter study provide dosing suggestions for various  
52 categories of patients. *Antimicrob Agents Chemother* 2011;55:3284-94.
- 53  
54  
55 32. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic  
56 analysis of colistin methanesulfonate and colistin after intravenous  
57  
58  
59  
60

- 1  
2  
3 administration in critically ill patients with infections caused by gram-negative  
4 bacteria. *Antimicrob Agents Chemother* 2009;53:3430-6.
- 5  
6  
7 33. European Medicines Agency completes review of polymyxin-based  
8 medicines.  
9  
10 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/news\\_and\\_events/news/](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002194.jsp&mid=WC0b01ac058004d5c1)  
11 [2014/10/news\\_detail\\_002194.jsp&mid=WC0b01ac058004d5c1](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002194.jsp&mid=WC0b01ac058004d5c1). Accessed 25  
12 August 2015.
- 13  
14 34. Couet W, Grégoire N, Marchand S, et al. Colistin pharmacokinetics: the fog is  
15 lifting. *Clin Microbiol Infect* 2012;18:30-9.
- 16  
17 35. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose  
18 of colistin methanesulphonate in critically ill patients: population  
19 pharmacokinetics, protein binding and prediction of bacterial kill. *Antimicrob*  
20 *Agents Chemother* 2012;56:4241-9.
- 21  
22 36. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of  
23 meropenem. *Clin Infect Dis* 2008;47(Suppl 1):S32-40.
- 24  
25 37. Infectious Diseases Society of America (IDSA), American College of Chest  
26 Physicians (ACCP), American Thoracic Society (ATS), et al. Recommended  
27 design features of future clinical trials of antibacterial agents for hospital-  
28 acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.  
29 *Clin Infect Dis* 2010;51(Suppl 1):S150-70.
- 30  
31 38. Powers JH. Recommendations for improving the design, conduct, and analysis  
32 of clinical trials in hospital-acquired pneumonia and ventilator-associated  
33 pneumonia. *Clin Infect Dis* 2010;51(Suppl 1):S18-28.
- 34  
35 39. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition,  
36 outcome measures, animal models, fluid therapy and information technology  
37 needs: the Second International Consensus Conference of the Acute Dialysis  
38 Quality Initiative (ADQI) Group. *Crit Care* 2004;8:R204-12.
- 39  
40 40. Kristofferson AN, Friberg LE, Nyberg J. Inter occasion variability in  
41 individual optimal design. *J Pharmacokinet Pharmacodyn* 2015;42:735-50.
- 42  
43 41. Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to  
44 carbapenem-resistant Enterobacteriaceae infections. *Emerg Infect Dis*  
45 2014;20:1170-5.
- 46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 42. Hussein K, Raz-Pasteur A, Finkelstein R, et al. Impact of carbapenem  
4 resistance on the outcome of patients' hospital-acquired bacteraemia caused  
5 by Klebsiella pneumonia. *J Hosp Infect* 2013;83:307-13.  
6  
7  
8 43. Balkan II, Aygün G, Aydın S, et al. Blood stream infections due to OXA-48-  
9 like carbapenemase-producing Enterobacteriaceae: treatment and survival. *Int*  
10 *J Infect Dis* 2014;26:51-6.  
11  
12 44. Efirid J. Blocked randomization with randomly selected block sizes. *Int J*  
13 *Environ Res Public Health* 2011;8:15-20.  
14  
15 45. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson  
16 comorbidity index and score for risk adjustment in hospital discharge abstracts  
17 using data from 6 countries. *Am J Epidemiol* 2011;173:676-82.  
18  
19 46. Falagas ME, Pitsouni EI, Bliziotis IA. Trends in the methodological quality of  
20 published randomized controlled trials on antibacterial agents. *Br J Clin*  
21 *Pharmacol* 2008;65:942-54.  
22  
23 47. Zimmermann JB, Horscht JJ, Weigand MA, et al. Patients enrolled in  
24 randomised clinical trials are not representative of critically ill patients in  
25 clinical practice: observational study focus on tigecycline. *Int J Antimicrob*  
26 *Agents* 2013;42:436-42.  
27  
28 48. Theuretzbacher U, Van Bambeke F, Cantón R, et al. Reviving old antibiotics.  
29 *J Antimicrob Chemother* 2015;70:2177-81.  
30  
31 49. Theuretzbacher U, Paul M. Revival of old antibiotics: structuring the re-  
32 development process to optimize usage. *Clin Microbiol Infect* Published  
33 Online First: 25 June 2015. doi: 10.1016/j.cmi.2015.06.019.  
34  
35 50. Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens in special  
36 populations. *Clin Microbiol Infect* Published Online First: 14 May 2015. doi:  
37 10.1016/j.cmi.2015.05.002.  
38  
39 51. Laterre PF, François B. Strengths and limitations of industry vs. academic  
40 randomised controlled trials. *Clin Microbiol Infect* Published Online First: 13  
41 July 2015. doi: 10.1016/j.cmi.2015.07.004.  
42  
43 52. Giske CG. Contemporary resistance trends and mechanisms for the old  
44 antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin.  
45 *Clin Microbiol Infect* Published Online First: 28 May 2015. doi:  
46 10.1016/j.cmi.2015.05.022.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 53. Andersson DI. Improving predictions of the risk of resistance development  
4 against new and old antibiotics. *Clin Microbiol Infect* Published Online First:  
5 21 May 2015. doi: 10.1016/j.cmi.2015.05.012.  
6  
7  
8 54. Muller AE, Theuretzbacher U, Mouton JW. Use of old antibiotics now and in  
9 the future from a pharmacokinetic/pharmacodynamic perspective. *Clin*  
10 *Microbiol Infect* Published Online First: 17 June 2015. doi:  
11 10.1016/j.cmi.2015.06.007.  
12  
13 55. Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use  
14 of colistin and polymyxin B: the Prato polymyxin consensus. *Lancet Infect Dis*  
15 2015;15:225-34.  
16  
17 56. Grégoire N, Mimoz O, Mégarbane B, et al. New colistin population  
18 pharmacokinetic data in critically ill patients suggesting an alternative loading  
19 dose rationale. *Antimicrob Agents Chemother* 2014;58:7324-30.  
20  
21 57. World Medical Association. World Medical Association Declaration of  
22 Helsinki: Ethical Principles for Medical Research Involving Human Subjects.  
23 *JAMA* 2013;310:2191-4.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60